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This dissertation is a systematic review comparing school based vaccination (SBV) strategies 
versus supplemental immunisation activities (SIAs) in the delivery of vaccines to 5-19 year 
olds in Africa. 
The protocol (Part A) outlines the rationale for this review, the study aim and the methods. The 
aim of the review was to compare the effectiveness of SIAs to SBV for the delivery of vaccines 
to 5-19 year olds in Africa. Effectiveness was measured in terms of vaccination coverage, cost 
of the vaccination strategy and effect of the strategy on routine immunisation. The protocol 
follows the PRISMA guidelines. 
The literature review (Part B) is a summary of the existing literature on the vaccination of 
school age children and adolescents in Africa. The literature review explores the burden of 
disease among school age children and adolescents and the challenges faced by existing 
structures in providing routine immunisation to this age group. It then ends by evaluating the 
use of complementary strategies to provide immunisation services to school aged children and 
adolescents. 
The manuscript (Part C) is presented in a format suitable for Plos Medical journal submission. 
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Immunisation is a key public health strategy that has been practiced since the discovery of 
smallpox vaccine in 1796 [1]. In 1974, the Expanded Programme on Immunisation (EPI), a 
global initiative aimed at a more optimal use of available vaccines was started [2]. Through 
EPI, millions of lives, especially those of young infants are saved every year [2]. However, 
vaccine preventable diseases (VPDs) still contribute a significant portion to the public health 
burden in many countries, especially those in Africa [3]. Globally, it is now appreciated that 
EPI alone, is not enough to optimize the benefits of available vaccines. 
There are multiple reasons which explain the relatively high burden of VPDs in some African 
countries. Among these reasons is the high prevalence of low vaccination coverage rates in 
some countries [4, 5]. High vaccination coverage rates are necessary to provide herd immunity 
against the targeted VPDs [6]. It is therefore important to assess other vaccination strategies 
that can be used to complement the EPI to maximize the benefits of available vaccines in the 
control of VPDs. 
In one of the many strategies to address the low vaccination coverage rates in some settings, 
the World Health Organisation (WHO) and the United Nations Children’s Fund (UNICEF) 
launched the Global Immunisation Vision and Strategy (GIVS) in 2006 [7].  The GIVS was a 
ten year framework aimed at helping countries immunise people of all age groups, by optimally 
using a wide range of available vaccines to reduce the morbidity and mortality of VPDs [7]. 
The GIVS recognized the need to extend the benefits of immunisation beyond childhood period 
[7]. The EPI is structured to deliver immunisation services during the childhood period and not 
to adolescents or adults. For GIVS to be successful there was a need to develop novel 
vaccination strategies to reach adolescents and adults with vaccines. 
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Five years post the GIVS initiation, an improvement in routine vaccination coverage as well as 
the use of new vaccines and reduction of mortality of certain VPDs was noted [8]. However, 
the need for more efforts in order to achieve the set goals for the global immunisation and child 
survival was also noted [8]. In 2011, the WHO in collaboration with member states launched 
the Global Vaccine Action Plan 2011-2020 (GVAP) in order to cater for the next decade of 
vaccination. The GVAP reinforced the goals of GIVS while adding new ones and providing 
guidelines to evaluate the impact of the plan [9]. Though the aims of GIVS and GVAP are to 
vaccinate people of all age groups, Africa has lagged behind in expanding the immunisation 
services to adolescents and adults [10]. In Africa, there is limited or absence of structured 
programmes to vaccinate school age children and adolescents.  
Immunisation in Africa is mostly carried out through the EPI. The aim of the EPI is to make 
immunisation services available to all children aged 0-5 years. With the development and 
licensing of new vaccines, the number of vaccines recommended for inclusion into EPI is 
rapidly growing [11] and also, the need to expand immunisation services to adolescents and 
adults [7, 9].  
The inclusion of vaccines targeting school age children and adolescents has been a challenge 
for several African countries because this age group does not correspond to that targeted by the 
EPI. The WHO classifies children aged 10 to 19 years as adolescents [12].  Some African 
countries have used school based vaccination (SBV) strategies and supplemental immunisation 
activities (SIAs) to deliver vaccines such as human papillomavirus (HPV), tetanus, rubella, 
measles and hepatitis B to school age children and adolescents [13, 14]. 
One of the key vaccines recommended by WHO for inclusion into routine programs which 
targets school age children and adolescents is the HPV vaccine. As of 2016, five African 
countries have introduced the HPV vaccine into their national programs while a further 22 have 
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conducted demonstration projects to assess feasibility of HPV vaccine introduction [15]. 
Almost all African countries have adopted a school based approach. This approach is used as 
the model of choice because it facilitates accessibility to the target population of girls aged 9 
to 13 years.  
Through the SBV strategy, two main options are used to select children to be vaccinated; the 
age of the child or the grade [14]. As recommended by WHO, the selected school age children 
receive two doses of the HPV vaccine with a six months interval [16, 17]. Several countries 
using this strategy have reported high vaccination coverage rates [18-20]. The success of this 
school based approach has been attributed to proper community sensitisation, and the use of 
existing health resources [20]. Nonetheless, several key challenges have been reported such as 
complex logistics to bring the immunisation services to the schools, low school attendance 
rates, inadequate finances, poor cervical cancer knowledge, school absenteeism and fear of side 
effects [21-24]. Supplemental immunisation activities could be used as an alternative to reach 
adolescents and adults in settings such as Africa, where the school enrolment rate is not 100%. 
Supplemental immunisation activities, also known as mass vaccination campaign refers to an 
immunisation strategy where a large number of people are vaccinated within a defined 
geographical area and period [25]. This is usually done in order to rapidly increase the 
immunity level of the target population in the face of an outbreak or potential outbreak. The 
SIAs are carried out to complement routine immunisation as well as during the introduction of 
a new vaccine into the routine immunisation programme [25]. The benefits of using SIAs to 
complement the routine immunisation programmes have been recognized for decades. The 
SIAs are reported to have an optimal vaccination coverage rate and are considered cost 
effective. Most importantly SIAs help in the control of VPDs [26-28]. Since 1988 they have 
helped reduce the global incidence of polio by 99% [29].  Similarly the use of SIAs targeting 
smallpox over several years   permitted the disease eradication by 1980 [25].  
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In comparison to the SBV, SIAs may be a better option for the delivery of vaccines to school 
age children as well as adolescents. SIAs could be used to deliver HPV vaccines as well as 
other adolescent vaccines against diseases such as tetanus, acellular pertussis, diphtheria and 
meningococcal disease [10, 30]. SIAs would permit harmonisation of the immunity levels of 
the population before the vaccine is delivered by the routine immunisation services, as is the 
case with HPV vaccine [25].  Recently, there are studies showing that HPV vaccine could 
potentially be delivered as a single dose schedule instead of the two dose schedule that is 
currently being used in most countries [31, 32].  The mobile and fixed strategies used during 
SIAs allow vaccinators to reach and vaccinate the target population irrespective of attendance 
or non-attendance of school. Using SIAs therefore, could have an advantage over the school 
based immunisation strategy in that mass vaccination ensures that everyone in the susceptible 
targeted population group has been immunised, hence closing the immunisation gap as 
recommended by the GIVS and GVAP initiatives [7, 9].  
Our systematic review study therefore proposes to evaluate the feasibility of using SIAs as an 
alternative to school based HPV vaccine delivery strategy, as well as the delivery of other 
adolescent vaccines in African countries. 
Objectives 
The objective of this systematic review is to compare the effectiveness of supplemental 
immunisation activities and school based vaccination strategies in the administration of 
vaccines to school age children and adolescents in Africa.  
METHODS 
Study registration 
This protocol will follow the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses Protocol 2015 (PRISMA-P) and is registered with PROSPERO CRD42017057475. 
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Criteria for considering studies for this review 
Types of studies 
Included studies will consist of randomised controlled trials (RCTs), non-RCTs, cluster-RCTs, 
interrupted time series, controlled before-and-after, cohort, cross-sectional and case-control 
studies. All included studies will be primary studies. Reviews will be excluded. 
Types of participants 
 Participants will include school age children and adolescents (5-19 years) living in Africa. 
Types of interventions 
Studies evaluating SIAs also called mass immunisation campaigns will be included. SIAs are 
mass vaccination campaigns within a defined geographical area and period regardless of the 
previous vaccination status of the target population [33] . Studies reporting on mass campaigns 
delivering services other than vaccination e.g. sensitisation as well as SIAs targeting age groups 
outside 5-19 years old will be excluded. 
Types of comparators 
Studies looking at school based vaccination strategies will be included. This strategy entails 
vaccinating children in schools either based on their grades or their ages. Depending on the 
vaccine, multiple doses may be administered at specified intervals. 
Types of outcome measures 
Primary outcome 
 Vaccination coverage
 Costs of vaccine delivery
Secondary outcome 
 Effects on routine vaccination/child health services
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Search method for identification of studies 
An extensive search will be carried out to identify all relevant studies. Both published and 
unpublished literature will be searched. No restriction will be placed on language or period. 
The following electronic databases will be searched for peer reviewed primary studies using 
both medical subject headings (MeSH) and free text terms relating to vaccination, children, 
adolescents and Africa; PubMed, Africa Wide, Cochrane Central Register of Controlled trials 
(CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAHL), World 
Health Organization Library Information System (WHOLIS), Web of Science, PDQ (Pretty 
Darn Quick)-Evidence and Scopus. The detailed search strategy is provided in the appendix 
(S1 Table). The following databases will also be searched for grey literature (reports, non-
reviewed and non-published papers); WHO, The Global Vaccine Alliance (GAVI) and 
UNICEF. We will browse reference lists of relevant publications to identify other potential 
studies.  
Data collection and analysis 
Selection of studies 
The titles and abstracts of eligible studies obtained through the search will be screened 
independently by two study team members. The two study team members will then 
independently read the full text of the retained studies and mark the studies for either inclusion 
or exclusion. Where differences arise the two team members will reach a consensus by 
discussion and if need be a third study team member will be consulted. The study selection 
process will be illustrated using the PRISMA flow chart.  
7 
Data extraction 
A data collection form will be designed and used independently by the two study team members 
to extract data from the included studies (S1 Form). The data extraction form will first be 
piloted by the two team members using the same studies to assess comprehension. In case of 
discrepancies with data extraction, the two study team members will discuss and if no 
agreement, a third study team member will be consulted and the differences will be resolved 
by consensus.  Data will be extracted on four main aspects; participants, intervention, 
comparison and outcomes.  
 Intervention/comparison: type of vaccination strategy (SBV or SIA), the aim of the
vaccination activity, its duration, the type and number of personnel carrying out the
vaccinations.
 Participants: age, gender, socio-economic status
 Outcomes: coverage, costs, effects on routine vaccination/child health  programs
Assessment of risk of bias in included studies 
Experimental studies will be assessed using the Cochrane Collaboration’s tool for assessing 
risk of bias [34]. The other study designs will be assessed using the Scottish Intercollegiate 
Guidelines Network (SIGN) checklist [35] and the Hoy modified tool [36] where applicable. 
The following biases will be assessed: 
 Selection bias: random sequence generation, concealment allocation, comparability of
groups at baseline
 Performance bias: blinding of participants and interviewers/care providers,
comparability of care between both groups
8 
 Attrition bias: percentage lost to follow-up, measures put in place to limit loss to follow-
up, non-response rate, missing outcome data
 Detection bias: blinding of assessors, methods used to measure outcomes
 Other biases
Studies assessed using the SIGN checklist will be scored as ‘High quality’, ‘Acceptable’ or 
‘Unacceptable’, those assessed using the Cochrane tool will be scored as ‘High risk’, ‘Low 
risk’, ‘Unclear’ and those assessed using the Hoy modified tool will be scored as ‘Low risk’, 
‘Moderate risk’ or High risk’ of bias. Where discrepancies arise, a consensus will be arrived at 
through discussion by the two reviewers and a third will be consulted if need be. 
Assessment of reporting biases 
A funnel plot will be constructed to assess the risk of publication bias per type of intervention 
if each intervention type included in the meta-analysis has over 10 studies of varying sizes. It 
will be examined for asymmetry visually and statistically using the Egger test and Harbord test 
[37, 38]. 
Data synthesis and analysis 
Data will be presented in text, tables and figures. An overview of the risk of bias of included 
studies will also be presented. Statistical analysis will be carried out using Stata v. 14.0. 
Results from studies reporting vaccination coverage will be expressed as percentages. Reported 
cost of vaccines shall be standardised to United States dollars (USD). The effects of the 
vaccination strategy (school based or SIA) on routine vaccination and health programmes will 
be expressed as the proportion of people in the catchment area seeking health services before 
and after the intervention. 
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Where data from the included studies is homogeneous, results will be pooled for meta-analysis 
using a random effects model due to probable clinical and methodological heterogeneity. 
Pooled statistics for vaccination coverage and effect on routine health programmes shall be 
expressed as risk ratios with their 95% confidence interval (95% CI) while those for cost of 
vaccines shall be expressed as the standardised mean difference (SMD) with its 95% CI. Where 
a meta-analysis cannot be carried out due to substantial heterogeneity, the results will be 
reported in a narrative form.  
Data will be pooled to assess heterogeneity. This will be assessed firstly by visually inspecting 
the forest plots. Secondly, the Chi-squared test for homogeneity with a significance level set at 
10% will be used. Finally, the I2 statistic will be used to quantify any statistically significant 
heterogeneity between study results and rated as ‘low’ for ≤ 49% and ‘moderate’ for 50-74% 
and ‘high’ for ≥ 75%. 
Efforts will be made to retrieve missing data by contacting the corresponding authors’ for the 
included studies. Where this is not possible, values will be imputed for primary outcomes in 
order to enable an intention-to-treat analysis. The other outcomes will be analysed with only 
available data. 
Subgroup analysis will be carried out based on the study design, type of vaccines, study setting 
and the age of the participants if possible. Sensitivity analysis will be carried out where 
imputations were done for the primary outcomes and also to determine if the study designs, 
study period or publication type have an impact on the results of the meta-analysis. 
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ETHICS 
Systematic reviews use publicly available data, and therefore do not require formal ethical 
review. Notwithstanding, this protocol shall be submitted to the University of Cape Town 
Departmental Research Committee for approval. The findings of this review shall be available 
online through the university library and shall also be submitted for publication in a peer-
reviewed journal. 
DISCUSSION 
Most vaccines in Africa are administered through the EPI hence leaving the 5-19 year olds 
vulnerable to some VPDs such as cervical cancer and group A meningococcal meningitis. 
According to WHO, in Africa, cervical cancer is responsible for 22% of all female cancers and 
23 per100,000 female deaths [39]. On the other hand Meningococcus A is responsible for large 
epidemics resulting in many deaths with nasal carriage highest among 5 – 14 year olds [40]. 
The importance of immunising this age group (5-19) is rapidly being appreciated by public 
health systems. Our review will generate useful data on the strategy that can best deliver 
vaccines to this population. 
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PART B: LITERATURE REVIEW 
1 
INTRODUCTION 
Vaccination has played a big role in the control, elimination and even eradication of some 
infectious diseases such as measles, polio and smallpox respectively [1, 2]. Nonetheless, some 
vaccine preventable diseases (VPDs) such as pneumococcal disease, cervical cancer and 
rotavirus still contribute significantly to the overall infectious diseases burden in Africa [3-5]. 
Several reasons, among them suboptimal vaccination coverage, lack of access as well as 
hesitancy to vaccination may explain the high burden of VPDs in Africa [6]. In order to mitigate 
the burden of VPDs, vaccination would have to be accessible to all age groups. The Expanded 
Programme on Immunisation (EPI) is the main platform used globally to provide childhood 
vaccination services. Extension of the immunisation services to school age children and 
adolescents has been recommended by the World Health Organisation (WHO) [7].  
School age children and adolescents are susceptible to VPDs due to reasons such as waning of 
the immunity achieved after childhood vaccination and lack of immunity against some VPDs 
targeting only this age group. To improve vaccination coverage in Africa, strategies such as 
Supplemental Immunisation Activities (SIAs) and School Based Vaccinations (SBV) are used 
in many settings to complement the EPI [8-10]. The SIAs and SBV strategies can target broader 
age group populations not normally included in the EPI. In addition, these two EPI 
complementary outreach strategies promote higher vaccination coverage which is a key 
element in the fight against VPDs. This review therefore focuses on the use of SIAs and SBVs 
as complementary strategies to the EPI in order to reduce the burden of VPDs in school age 
children and adolescents. 
SECTIONS OF THE REVIEW 
The first section explores the burden of specific VPDs among school age children as well as 
adolescents in Africa. The second section gives an overview of the challenges faced by the EPI 
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in providing vaccines to school age children and adolescents. The last section evaluates the 
utilisation of SIAs and SBV as complementary strategies to reach school age children and 
adolescents with vaccination services.  
SEARCH STRATEGY 
Key terms such as vaccines, mass campaigns, immunisation, immunization, school based 
immunisation, adolescent and school age children were used to identify the relevant literature. 
The following electronic databases and websites were searched for peer-reviewed journals or 
reports: PubMed, Africa Wide, UpToDate, CINAHL, WHOLIS, CENTRAL the World Health 
Organisation (WHO) website and Google Scholar. 
No restriction was placed on the type of study design, study period or language. Articles or 
reports that reported about vaccination in children or adolescents were included as well as 
studies that focused on SIAs or SBVs. 
IMPORTANCE OF VACCINATING SCHOOL AGE CHILDREN AND 
ADOLESCENTS  
Overview 
Vaccine preventable diseases (VPDs) have one distinct characteristic: there exists a vaccine 
capable of preventing the infection. The WHO list 25 VPDs whose vaccines already exist [11]. 
Future vaccines against infectious diseases such as Mycobacterium tuberculosis (M.tb), HIV, 
ebola, zika, malaria among others are under development [11]. In comparison to adults, infants 
are at the highest risk of contracting VPDs because they have a “naïve” immune system against 
the disease causing pathogens [12]. From birth until a few months later, babies are immune to 
very few pathogens like the measles virus due to antibodies acquired from their mothers [12]. 
Immunity to other pathogens can only be acquired either through vaccination or natural 
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infection [12]. Therefore; the EPI in most countries mainly focuses on immunising during the 
childhood phase of life to protect the young infants from infectious pathogens. The need to 
vaccinate school age children and adolescents has recently become a very topical issue in 
vaccinology [13]. 
There are several reasons that make vaccination of school age children and adolescents 
important. First is catch up as some infants miss routine vaccinations delivered via EPI leaving 
these children susceptible to VPDs [7, 14]. Second, for some VPDs such as tetanus, diphtheria 
and pertussis, immunity acquired after infant immunisation wanes over time thus requiring 
booster doses later in life to sustain the immunity [15]. Third, some VPDs such as rubella have 
shown a shift in age distribution from infancy to adolescence in some settings [7, 16]. Finally, 
new vaccines such as HPV are developed to target pre-adolescent and adolescent age groups 
[10] and it is also likely that future vaccines against HIV will target adolescents.
The WHO recommends addition of vaccines targeting older children into national EPIs or the 
extension of existing ones to the older age groups [17]. The vaccines recommended for school 
age children and adolescents include HPV, diphtheria, tetanus, pertussis, measles, rubella, 
hepatitis B and meningococcal disease [7, 17]. In agreement with the WHO recommendations, 
a majority of High Income Countries (HICs) now routinely vaccinate older children and 
adolescents [18, 19]. However, implementation of the WHO recommendations to vaccinate 
older children and adolescents has been slow in most of the Low and Middle Income Countries 
(LMICs) [13].  
In Africa, weak surveillance systems are prevalent partly due to underfunding and competing 
interests [20]. As a result, data on the regional burden of many VPDs among older children and 
adolescents is limited in Africa. Lack of epidemiological data may be another barrier to the 
inclusion of the vaccines recommended by the WHO for older children and adolescents into 
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national EPIs in Africa [21]. Below, we discuss some reported information on the burden of 
VPDs for which the WHO has recommended vaccinations for, among school age children and 
adolescents.  
Disease burden 
 Cervical cancer, preventable by HPV vaccine
The human papillomavirus (HPV) is a necessary cause for the development of cervical cancer 
[22]. Depending on the serotype of the virus, infection can lead to low risk genital infection or 
high risk invasive cancers [23]. Cervical cancer is the third most common cancer in women 
worldwide and one of the leading causes of cancer related deaths among women in developing 
countries [24]. In Africa, according to the 2015 WHO report, cervical cancer was responsible 
for 22% of all female cancers, and 23 per 100,000 female deaths per year [24]. A study carried 
out in Burkina Faso among adolescents showed that 41.5% of the study population tested 
positive for at least one high risk HPV genotype [25]. Similarly, 64.7% South African women 
were reported to be positive for at least one high risk HPV genotype [26]. The HPV infection 
and consequently cervical cancer can be prevented by the vaccination of 9-14 year old girls 
with the HPV vaccine [17]. 
 Diphtheria, Tetanus and Pertussis preventable by Tdap (Tetanus, Diphteria, Acellular
Pertussis) vaccine
Diphteria is a bacterial infection caused by the toxin producing Corynebacterium diphtheriae. 
C. diphtheriae is transmitted through contact with respiratory droplets or skin lesions [27]. Due
to vaccination, diphtheria is becoming a rare disease globally. In 2015 there were 4530 reported 
cases globally [28]. However, the disease is still sporadic in many parts of the world [29] and 
remains a public health problem in countries with low vaccination coverage [28]. School age 
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children and adolescents can be protected from diphtheria by receiving a booster dose of the 
Tdap vaccine [17].  
Pertussis also known as whooping cough is caused by the bacteria Bordetella pertussis. 
Infection occurs through direct contact with secretions from the nose or mouth of an infected 
person [30]. Adolescent infection has been largely attributed to waning immunity obtained 
after immunisation early in life [15, 31]. Studies suggest that adolescent and adult infection 
serve as the source of infection to younger children [30, 32]. A study carried out among 
adolescents in South Africa showed that 15% of the study group did not show any detectable 
antibody titres against pertussis [33]. Furthermore, in the same study, among the adolescents 
with detectable antibody levels, it was not known if these titres were protective [33]. School 
age children 5-6 years can be protected from pertussis by receiving a booster dose of a whole 
cell pertussis (wP) containing vaccine while older children can receive a booster dose of the 
Tdap vaccine [17].  
Tetanus is caused by spores from the bacteria Clostridium tetani. These spores are found in the 
soil and cause infection when they enter a flesh wound. Tetanus still remains a threat to many 
lives in Africa. Maternal and neonatal tetanus were targeted for global elimination by 2015 but 
only 27 countries in Africa have achieved this goal as of 2017 [34, 35]. A study conducted by 
Scobie et al., in three African countries showed that children aged 5-14 had a lower immunity 
to tetanus than those <5 years, and men ≥ 15 years had a lower immunity compared to women 
[36]. Another study carried out in Ivory Coast evaluated the mortality and morbidity of tetanus 
among children 0 – 15 years and showed that 59.5% of the cases admitted in hospital were > 5 
years and 22% of them died [37]. Children aged 5-14 and men ≥15 are the most vulnerable 
group in Africa due to the waning immunity. Anti-tetanus toxoid (ATT) or booster doses of the 
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Tdap vaccine should also be administered to school age children and adolescents to prevent 
tetanus [17].  
 Hepatitis B, preventable by Hepatitis B vaccine
Hepatitis B is a viral liver disease caused by the Hepatitis B virus (HBV). The HBV is 
transmitted through contact with infected bodily fluids (blood, semen, saliva). The WHO 
estimates that 5-10% of the general population in Africa live with the virus [38]. Most children 
and adolescents infected with HBV are also co-infected with HIV. A study carried out in 
Tanzania among children and adolescents showed that 9.6% of the study population was 
HIV/HBV co-infected [39] while another study carried out in Zambia reported a similar 
infection burden of 10.4% [40]. According to the WHO recommendations, school age children 
and adolescents at high risk for Hepatitis B who were not immunised in infancy should receive 
3 doses Hepatitis B vaccine in order to prevent disease [17]. 
 Measles and Rubella  preventable by MMR (Measles, Mumps, Rubella) vaccine
Measles is caused by the measles virus. Infection occurs through inhalation of droplets from 
respiratory or throat secretions from an infected person. The introduction of the measles 
vaccine has led to a significant drop in the number of measles cases globally [41]. However, 
measles still remains endemic in some parts of Africa and Asia [41]. Large epidemics can still 
be seen in parts of Southern Africa and this is threatening the achievement of the WHO goal 
of eliminating measles by 2020 [42]. As of February 2017, Africa registered 36260 cases 
compared to 55263 in 2016 [43]. Due to under reporting, the true burden of the measles disease 
is believed to be much greater in Africa and globally. Measles mostly affects children but cases 
have also been reported among adolescents and adults. Adult infection occurs usually in the 
case where the person missed their routine infant vaccination or received only one dose of the 
measles vaccine [7]. A study carried out by Goodson et al., showed that the mean age of 
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measles cases in Africa was 79 months [44]. Measles infection in school aged children and 
adolescents can be prevented by the administration of 2 doses of measles vaccine alone or in 
combination [17]. 
Congenital rubella syndrome which results from a pregnant women infected with rubella 
passing the virus to her foetus is the most devastating form of rubella [45]. A review conducted 
by Goodson et al., on the epidemiology of rubella in Africa showed that the infection occurred 
across all age groups with 68% of cases occurring in people ≥ 4 years and 5% among women 
of child-bearing age [46]. Rubella is detected through the surveillance system designed for 
measles hence many cases may be misclassified as measles. Children 5-19 years are at risk of 
acquiring the disease due to the shift in the age group infected by rubella. Nonetheless, 
vulnerable populations to rubella can be protected by administration of at least one dose of the 
MMR vaccine [17]. 
 Meningococcal meningitis, preventable by PsA-TT vaccine
Neisseria meningitidis is responsible for a majority of meningitis cases in Africa. Most cases 
occur within the Sub-Saharan meningitis belt which is made up of 26 countries [47]. N. 
meningitis group A is responsible for most of the disease in this region but other serotypes B, 
C, W and X have recently caused epidemics too [48, 49]. Nasal carriage of the bacteria has 
been shown to be highest among 5-14 year olds [50]. The introduction of a vaccine against 
meningoccocus A (PsA-TT) in 2010 has led to a significant drop in the incidence of disease 
caused by the serotype A [51]. Lingani et al., reported an incidence rate of 0.27 cases per 
100,000 inhabitants in 10 countries in the belt before the introduction of the vaccine in 2010 
compared to 0.02 cases per 100,000 inhabitants in 2011-2013 after the vaccine introduction 
[52]. School aged children and adolescents who are at risk for meningitis A can prevent the 
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spread of the bacteria or getting the disease by being vaccinated with one dose of PsA-TT 
vaccine [51]. 
THE CHALLENGES OF THE EPI IN DELIVERING VACCINES TO SCHOOL AGE 
CHILDREN AND ADOLESCENTS 
The EPI has been successful in Africa with vaccination coverage of the third dose of the 
diphtheria, tetanus, pertussis vaccine (DTP3) increasing from 8% in 1980 to 76% in 2015 [53]. 
Periodically, new vaccines are being recommended by WHO for addition into national EPI 
programmes. Some of these new vaccines now target school age children and adolescents [17]. 
However, introduction of the new vaccines by African national immunisation programmes 
(NIPs) has been slow. The EPI in Africa is faced with several challenges ranging from 
suboptimal policies to poor service delivery which prevents the programme from meeting the 
target coverage among the primary target population (0-5 years). In our view, in order to extend 
routine immunisation services to older age groups, the African EPI would have to overcome 
the following challenges; 
 Policies, programme management
Most African countries do not have adequate policies and guidelines for immunisation which 
define the roles of each stakeholder and describe the standard operating procedures for 
vaccination, monitoring, disease surveillance, data management or communication [54]. This 
leads to confusion of leadership roles and poor ownership of the programme especially at the 
periphery [55].  There is little or no evidence to inform on which sectors need reinforcement 
or which new vaccines need to be introduced [6]. Strengthening of the programme management 
is therefore critical to address the EPI challenges in Africa. 
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 Sustainable financing
National EPIs are subject to budget cuts due to competing national programmes. These budget 
cuts are motivated by high vaccination coverage or absence of outbreaks. On the other hand 
there is low sourcing for funds from donors [55]. The low funding leads to a drop in the quality 
of services and the inability to meet the agreements signed with international partners such as 
The Global Vaccine Alliance (GAVI), 
The GAVI finances the introduction of new vaccines into NIPs for most African countries [56]. 
The initiative also finances demonstration projects such as for HPV vaccine introduction, mass 
campaigns (measles-rubella, meningitis A) or provides introduction grants in GAVI eligible 
countries. The GAVI beneficiary countries are supposed to self-finance routine delivery of the 
vaccines within several years of the campaigns [56]. However, many countries still lag behind. 
 Service delivery
The EPI uses health facilities as its main delivery centre in addition to the outreach strategy 
which entails providing services to children several kilometres away from the nearest health 
facilities.  Unfortunately, some older children including adolescents, hardly use health services 
for different reasons; perceived sub-optimal care provided by the health facilities, lack of 
finances to pay for services, preoccupation with other activities during the day such as school, 
self-perceived state of good health [57, 58]. A more structured platform is therefore needed to 
make vaccines accessible to this older age group. 
Understaffing is a challenging issue that is routinely reported by many of the EPI centres. 
Coupled to the understaffing is the high staff turnover and reliance on in service training. The 
end result is vaccinators and managers are not adequately skilled to carry out their functions 
which require a degree of specialty [6]. The staff shortage has led to the use of community 
health workers as vaccinators who are less skilled and knowledgeable and prone to cause more 
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immunisation errors [54]. Increasing the number of staff required to cater for the older children 
places a considerable strain on an already stretched programme [59]. 
 Cold chain and logistics management
Extending services to older children means an increase in the quantity of vaccines that need 
storage, transporting and tracking. This implies increasing the capacity of the cold chain and 
logistics management at the national and district levels. Vaccine storage is already a concern 
in most settings especially those that lack electricity [6]. Inadequate storage and transport can 
destroy vaccines leading to huge financial ramifications as the new vaccines are more 
expensive than the regular vaccines [54].  Poor stock management due to inadequate supply 
and distribution of vaccines and consumables leads to vaccine stock outs in some areas and 
overstocking in others.  
 Communication, community involvement and advocacy
Low community awareness of vaccination services, inadequate follow-up of parents by health 
staff, stock out of vaccines at vaccination centres and poor handling of rumours generated after 
an adverse event following immunisation (AEFI) are reported as major obstacles preventing 
the EPI from attaining its goal [54, 59].  
COMPLEMENTARY IMMUNISATION STRATEGIES TO REACH SCHOOL AGE 
CHILDREN AND ADOLESCENTS 
Overview 
The foundation of routine immunisation in most countries is the EPI. Through EPI, several 
vaccines delivery strategies to the target populations are used. As the delivery of vaccination 
services through the EPI are mainly done at a health facility, additional vaccination delivery 
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methods are necessary to reach populations such as school age children and adolescents whose 
contacts with health facilities are infrequent. The additional vaccine delivery strategies used 
usually depend on the objectives of the vaccination programmes. These vaccination delivery 
strategies include fixed, outreach, mobile or door-to-door [60]. 
 Fixed: This strategy involves the delivery of vaccines by health workers at an existing
health facility. Vaccination is usually rendered every day or on specific days throughout
the week.
 Outreach: Involves the delivery of vaccines by health workers or volunteers at a location
in the community other than the regular vaccination site on specific dates. The location and
vaccination dates are usually publicised well in advance.
 Mobile: Involves a team of health workers and volunteers who travel to hard to reach areas
such as islands and mountainous villages to administer vaccines to the target population.
This team usually spends several days vaccinating the community.
 Door-to-door: A team of volunteers and health workers move from house to house
vaccinating the target population.
To extend the benefits of immunisation to school age children and adolescents, routine 
immunisation can broadly utilize SIAs and SBVs. 
Supplemental Immunisation Activities (SIAs) strategy 
The SIAs, also known as mass vaccination campaigns involve fixed, outreach, door-to-door 
and mobile strategies aimed at vaccinating a large number of people within a short period 
regardless of their previous vaccination status [1]. The fixed strategy involves using existing 
vaccination sites like health facilities while the other strategies entail vaccinating the target 
population in their homes or at local gatherings such as markets, churches, schools. 
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Due to its door-to-door component, SIAs have the capacity to reach a majority of the target 
population resulting in a better vaccination coverage which provides the herd immunity needed 
to prevent disease transmission. This property of SIAs makes it useful for several immunisation 
objectives: 
 Eradication: SIAs were used for the eradication of smallpox in 1980 [1] and are
currently being used for the eradication of polio by 2018 [61].  Smallpox is the only
disease to achieve an eradication status after global vaccination efforts from 1966-1980.
Polio is the next disease targeted for eradication. Synchronised SIAs are being carried
out in endemic and susceptible countries to break transmission of wild and vaccine
derived poliovirus [62].
 Control of outbreaks: SIAs are used during outbreaks to quickly interrupt disease
transmission. These outbreaks usually occur due to poor vaccination coverage achieved
during routine immunisation or infection in populations not covered by the EPI. This
has been the case with measles, yellow fever and cholera. SIAs used during such
outbreaks target infant to adult populations [63-65].
 Introduction of new vaccines into the EPI: New vaccines are often being recommended
by WHO for addition into national EPIs. The high vaccination coverage achieved
during SIAs allows for the harmonisation of the immunity levels of the target
population before its delivery through EPI. This was the case with the introduction of
the meningococcal meningitis vaccine MenAfricVac in the Sub-Saharan African
meningitis belt in 2010. Mass vaccination campaigns targeting people aged 1-29 were
carried out in 15 countries [66, 67]. These countries were encouraged to include the
vaccine into the national EPIs within 1-5 years after the mass campaign.
Despite these benefits, SIAs have been thought to negatively impact routine immunisation and 
health systems. Some reports argued that during SIAs, routine immunisation activities and 
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regular activities in the health facilities are interrupted [66]. Moreover, frequent SIAs targeting 
different diseases may make care-givers reluctant to take their children to clinics for routine 
vaccines thinking it will be delivered at home [68, 69]. On the other hand, resources, both 
human and financial that would have been spent on strengthening the EPI are thought to be 
spent on planning for the SIA, vaccinators, transport for mobile teams and much more [70, 71]. 
School Based Vaccination (SBV) strategy 
The SBV is an outreach strategy which involves vaccination of children enrolled in school and 
within the school grounds during or after school hours. This strategy takes into account the 
previous vaccination status of the child and should not be confused with vaccination of children 
in schools during SIAs. The target group of the children is determined by their age or grade. 
This strategy has been widely used for the delivery of HPV vaccine to young girls in Africa 
[72].  
Several benefits have been associated with this mode of service delivery for vaccines targeting 
school age children especially HPV. First, one of the aims of routine immunisation is to 
vaccinate all persons eligible and SBV has been shown to achieve a high coverage [73]. In 
most settings, a majority of children aged 5 to 19 years are enrolled in schools though this may 
vary depending on urban or rural areas. Hence vaccinating children in schools ensures a high 
vaccination coverage [73]. Second, SBV facilitates the administration of vaccines requiring 
several doses. Older children who hardly use health services may fail to return for subsequent 
doses of a vaccine delivered at a health centre thus a school setting facilitates the follow up and 
vaccination of students who missed a dose [74, 75]. Third, SBV enables adequate planning and 
resource management. The exact number of children targeted is known beforehand by using 
school registers hence, sufficient vaccines and related materials can be ordered and stored 
adequately [74]. Fourth, SBV helps increase awareness of diseases in the community. Before 
any vaccination session, caretakers are invited for an education meeting or the children are 
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given information packs and consent forms which they hand to their caretakers. In several 
settings, female caretakers of targeted girls for vaccination have been offered HPV screening 
[75, 76]. Lastly, other health services such as deworming can be delivered alongside SBV [77] 
as well as increased benefits of bringing partnership between health and education departments. 
The delivery of HPV through school based vaccination has faced several challenges. First is 
the identification of the target vaccination group using the learners’ grade as a criteria. The 
WHO recommends vaccination of children 9-14 years old. Using the grade criteria, grade 4 to 
6 is usually targeted for vaccination because most of the learners fall within the specified age 
group. However, this brings confusion because children who do not meet the age criteria are 
found in grades 4 to 6 [74, 78]. Second, girls who do not attend school do not have the 
opportunity to get the HPV vaccine [78]. This can be problematic in areas with low school 
attendance rates. In some settings the vaccine is made available at the health centre for a limited 
period for girls who do not attend school or missed school during the vaccination session [76]. 
Related to this second point, a substantial number of girls in private schools, for example in 
South Africa, do not get free HPV vaccination from the government. Third is the sensitisation 
of the learners and guardians. Consent from guardians is a requirement before children can be 
vaccinated in schools or during SIAs. These guardians include both the teachers and the legal 
guardians. Vaccination is hampered when head teachers refuse vaccination of children in their 
schools and in the case where school vaccination has been permitted, legal guardians do not 
consent [74, 76]. 
CONCLUSION 
Vaccine preventable diseases remain a public health burden for Africa but the availability of 
vaccines combined with the best vaccine delivery strategy can alleviate this burden. The EPI 
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has been largely successful in delivering vaccines to children < 5 years although a lot can be 
done to improve. However, due to the epidemiological changes of some VPDs and the 
development of new vaccines, vaccines targeting older children are now recommended for 
inclusion into the EPI. Strategies such as SIAs and SBV can be used by the EPI to reach school 
age children and adolescents. In the presence of resource constraints as is in the case in Africa, 
NIPs may be required to use SIAs or SBV.  Systematised evidence is not available on which 
strategy would be more effective. We therefore planned a systematic review to evaluate which 
strategy (SIA or SBV) is more effective for the delivery of vaccines to 5-19 year olds in Africa. 
REFERENCES 
1. Heymann DL, Aylward RB. Mass vaccination: when and why. Curr Top Microbiol Immunol.
2006;304:1-16.
2. Maurice J. And then there were two...polio-endemic countries. Lancet. 2015;386(10003):1521-
2.
3. De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, et al. The
burden of human papillomavirus infections and related diseases in sub-saharan Africa. Vaccine.
2013;31 Suppl 5:F32-46.
4. Dennehy PH. Rotavirus Infection: A Disease of the Past? Infect Dis Clin North Am.
2015;29(4):617-35.
5. Adegbola RA, DeAntonio R, Hill PC, Roca A, Usuf E, Hoet B, et al. Carriage of Streptococcus
pneumoniae and other respiratory bacterial pathogens in low and lower-middle income
countries: a systematic review and meta-analysis. PloS one. 2014;9(8):e103293.
6. Machingaidze S, Wiysonge CS, Hussey GD. Strengthening the expanded programme on
immunization in Africa: looking beyond 2015. PLoS Med. 2013;10(3):e1001405.
7. Mackroth MS, Irwin K, Vandelaer J, Hombach J, Eckert LO. Immunizing school-age children
and adolescents: experience from low-and-middle-income countries. Vaccine.
2010;28(5):1138-47.
16 
8. Bernhardt GL, Cameron NA, Willems B, Boulle A, Coetzee D. Measles vaccination coverage
in high-incidence areas of the Western Cape, following the mass vaccination campaign. S Afr
Med J. 2013;103(3):181-6.
9. Gammino VM, Nuhu A, Gerber S, Gasasira A, Sugerman DE, Manneh F, et al. An evaluation
of polio supplemental immunization activities in Kano, Katsina, and Zamfara States, Nigeria:
lessons in progress. J Infect Dis. 2014;210 Suppl 1:S91-7.
10. Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage
in Rwanda's national human papillomavirus vaccination programme. Bull World Health Org.
2012;90(8):623-8.
11. World Health Organisation. Immunisation, vaccines and biologicals: Vaccines and disease.
2017. Available from: http://www.who.int/immunization/diseases/en/. Accessed 24/04/17.
12. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from
infancy to old age. Proc Biol Sci. 2015;282(1821):20143085.
13. Stevens W, Walker D. Adolescent vaccination in the developing world: time for serious
consideration? Vaccine. 2004;22(5-6):781-5.
14. Beran J, Van Der Meeren O, Leyssen M, D'Silva P. Immunity to hepatitis A and B persists for
at least 15 years after immunisation of adolescents with a combined hepatitis A and B vaccine.
Vaccine. 2016;34(24):2686-91.
15. Bechini A, Tiscione E, Boccalini S, Levi M, Bonanni P. Acellular pertussis vaccine use in risk
groups (adolescents, pregnant women, newborns and health care workers): a review of
evidences and recommendations. Vaccine. 2012;30(35):5179-90.
16. Thayyil J, Kuniyil V, Moorkoth AP, Rao B, Selvam P. Prevalence of rubella-specific IgG
antibodies in unimmunized young female population. J Fam Med Prim Care. 2016;5(3):658-
62.
17. World Health Organisation. Immunisation, vaccines and biologicals: WHO recommendations
for routine immunization - summary tables. Table 1. 2016. Available from:
http://www.who.int/immunization/policy/immunization_tables/en/ Accessed 07/10/17.
18. Ventola CL. Immunization in the United States: Recommendations, Barriers, and Measures to
Improve Compliance: Part 1: Childhood Vaccinations. P T. 2016;41(7):426-36.
19. Hilton S, Patterson C, Smith E, Bedford H, Hunt K. Teenagers’ understandings of and attitudes
towards vaccines and vaccine-preventable diseases: A qualitative study. Vaccine.
2013;31(22):2543-50.
20. Adokiya MN, Awoonor-Williams JK, Beiersmann C, Müller O. The integrated disease
surveillance and response system in northern Ghana: challenges to the core and support
functions. BMC Health Ser Res. 2015;15(1):288.
21. World Health Organisation. WHO Report on Global Surveillance of Epidemic-prone




22. Chua KL, Hjerpe A. Persistence of human papillomavirus (HPV) infections preceding cervical
carcinoma. Cancer. 1996;77(1):121-7.
23. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the
role of human papillomavirus infection. CMAJ. 2001;164(7):1017-25.
24. Msyamboza KP, M'Bang'ombe M, Hausi H, Chijuwa A, Nkukumila V, Kubwalo HW, et al.
Feasibility and acceptability of oral cholera vaccine mass vaccination campaign in response to
an outbreak and floods in Malawi. PAMJ. 2016;23:203.
25. Ouédraogo CMR, Rahimy RML, Zohoncon TM, Djigma FW, Yonli AT, Ouermi D, et al.
[Epidemiology and characterization of high-risk genotypes of human Papillomavirus in a
population of sexually active adolescents in Ouagadougou]. J Gynecol Obstet Biol Reprod.
2015;44(8):715-22.
26. Adler DH, Wallace M, Bennie T, Mrubata M, Abar B, Meiring TL, et al. Cervical dysplasia
and high-risk human papillomavirus infections among HIV-infected and HIV-uninfected
adolescent females in South Africa. Infect Dis Obstet Gynecol. 2014;2014:498048. doi:
10.1155/2014/498048
27. Hadfield TL, McEvoy P, Polotsky Y, Tzinserling VA, Yakovlev AA. The pathology of
diphtheria. J Infect Dis. 2000;181 Suppl 1:S116-20.
28. Vannice KS, Keita M, Sow SO, Durbin AP, Omer SB, Moulton LH, et al. Active Surveillance
for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal
Conjugate Vaccine (PsA-TT) in Mali. Clin Infect Dis. 2015;61 Suppl 5:S493-500.
29. Mattos-Guaraldi AL, Moreira LO, Damasco PV, Hirata Junior R. Diphtheria remains a threat
to health in the developing world--an overview. Mem Inst Oswaldo Cruz. 2003;98(8):987-93.
30. Kampmann B, Mackenzie G. Morbidity and Mortality Due to Bordetella pertussis: A
Significant Pathogen in West Africa? Clinical Infect Dis.2016;63 Suppl 4:S142-7.
31. Leung AK, Robson WL, Davies HD. Pertussis in adolescents. Adva Ther. 2007;24(2):353-61.
32. Benamrouche N, Tali Maamar H, Lazri M, Hasnaoui S, Radoui A, Lafer O, et al. Pertussis in
north-central and northwestern regions of Algeria. J Infect Dev Ctries. 2016;10(11):1191-9.
33. Rensburg MA, Esser M, de Beer C. The seroprevalence of Bordetella pertussis antibodies in
adolescents in the Western Cape. S Afr J Infect Dis. 2013;28(4):202-6.
34. World Health Organisation. Tetanus. 2016. Available from:
http://www.wpro.who.int/mediacentre/factsheets/fs_20120307_tetanus/en/ Accessed
24/04/16. 
35. UNICEF. Elimination of maternal and neonatal tetanus. 2017. Available from:
https://www.unicef.org/health/index_43509.html Accessed 24/04/17.
18 
36. Scobie HM, Patel M, Martin D, Mkocha H, Njenga SM, Odiere MR, et al. Tetanus Immunity
Gaps in Children 5-14 Years and Men >/= 15 Years of Age Revealed by Integrated Disease
Serosurveillance in Kenya, Tanzania, and Mozambique. Am J Trop Med Hyg. 2017;96(2):415-
20.
37. Aba YT, Cisse L, Abale AK, Diakite I, Kone D, Kadiane J, et al. [Neonatal and child tetanus
morbidity and mortality in the University hospitals of Abidjan, Cote d'Ivoire (2001-2010)]. Bull
Soc Pathol Exot. 2016;109(3):172-9.
38. Colombini A, Trotter C, Madrid Y, Karachaliou A, Preziosi MP. Costs of Neisseria
meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso. Clin
Infect Dis. 2015;61 Suppl 5:S473-82.
39. Muro FJ, Fiorillo SP, Sakasaka P, Odhiambo C, Reddy EA, Cunningham CK, et al.
Seroprevalence of Hepatitis B and C Viruses Among Children in Kilimanjaro Region,
Tanzania. J Pediatr Infect Dis Soc. 2013;2(4):320-6.
40. Peebles K, Nchimba L, Chilengi R, Bolton Moore C, Mubiana-Mbewe M, Vinikoor MJ.
Pediatric HIV-HBV Coinfection in Lusaka, Zambia: Prevalence and Short-Term Treatment
Outcomes. J Trop Pediatr. 2015 Dec;61(6):464-7.
41. World Health Organisation. Immunisation, vaccines and biologicals: Measles. 2014. Available
from: http://www.who.int/immunization/topics/measles/en/ Accessed 19/05/2017.
42. Shibeshi ME, Masresha BG, Smit SB, Biellik RJ, Nicholson JL, Muitherero C, et al. Measles
resurgence in southern Africa: challenges to measles elimination. Vaccine. 2014;32(16):1798-
807.
43. World Health Organisation. Immunisation, Vaccines and Biologicals: Measles surveillance
data. 2017. Available from:
http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/acti
ve/measles_monthlydata/en/ Accessed 06/03/17.
44. Goodson JL, Masresha BG, Wannemuehler K, Uzicanin A, Cochi S. Changing epidemiology
of measles in Africa. J Infect Dis. 2011;204 Suppl 1:S205-S14.
45. Chimhuya S, Manangazira P, Mukaratirwa A, Nziramasanga P, Berejena C, Shonhai A, et al.
Trends of rubella incidence during a 5-year period of case based surveillance in Zimbabwe.
BMC Pub Health. 2015;15(1):294.
46. Goodson JL, Masresha B, Dosseh A, Byabamazima C, Nshimirimana D, Cochi S, et al.
Rubella Epidemiology in Africa in the Prevaccine Era, 2002–2009. J Infect Dis.
2011;204(suppl_1):S215-S25.
47. Hart CA, Cuevas LE. Meningococcal disease in Africa. Ann Trop Med Parasitol.
1997;91(7):777-85.
48. Mohammed I, Iliyasu G, Habib AG. Emergence and control of epidemic meningococcal
meningitis in sub-Saharan Africa. Pathog Glob Health. 2017;111(1):1-6.
19 
49. Delrieu I, Yaro S, Tamekloe TA, Njanpop-Lafourcade BM, Tall H, Jaillard P, et al. Emergence
of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS
One. 2011;6(5):e19513.
50. Vetter V, Baxter R, Denizer G, Sáfadi MAP, Silfverdal SA, Vyse A, et al. Routinely vaccinating
adolescents against meningococcus: targeting transmission & disease. Expert Rev Vaccines.
2016;15(5):641-58.
51. Meningitis control in countries of the African meningitis belt, 2015. Wkly Epidemiol Rec.
2016;91(16):209-16.
52. Lingani C, Bergeron-Caron C, Stuart JM, Fernandez K, Djingarey MH, Ronveaux O, et al.
Meningococcal Meningitis Surveillance in the African Meningitis Belt, 2004-2013. Clin Infect
Dis. 2015;61 Suppl 5:S410-S5.
53. World Health Organisation. immunization, Vaccines and Biologicals: Data and Statistics.
2017.  Available from:
http://www.who.int/immunization/monitoring_surveillance/data/AFR/en/ Accessed 31/03/17.
54. Shen AK, Fields R, McQuestion M. The future of routine immunization in the developing
world: challenges and opportunities. Glob Health Sci Prac. 2014;2(4):381-94.
55. Mihigo R, Anya B, Okeibunor J, Poy A, Machingaidze S, Wiysonge CS, et al. Routine
immunization in the WHO African Region: Progress, challenges and way forward. African
Health Monitor. 2015(19).
56. GAVI, The Vaccine Alliance. New and underused vaccine support. 2017. Available from:
http://www.gavi.org/support/nvs/ Accessed 04/06/2017.
57. Haddison EC, Nguefack-Tsagué G, Noubom M, Mbatcham W, Ndumbe PM, Mbopi-Kéou F-
X. Voluntary counseling and testing for HIV among high school students in the Tiko health
district, Cameroon. Pan Afr Med J. 2012;13:18.
58. Otwombe K, Dietrich J, Laher F, Hornschuh S, Nkala B, Chimoyi L, et al. Health-seeking
behaviours by gender among adolescents in Soweto, South Africa. Glob Health Act.
2015;8:10.3402/gha.v8.25670.
59. Wiysonge CS, Ngcobo NJ, Jeena PM, Madhi SA, Schoub BD, Hawkridge A, et al. Advances
in childhood immunisation in South Africa: where to now? Programme managers' views and
evidence from systematic reviews. BMC Pub Health. 2012;12:578.
60. Immunisation programme managemnt. The Open University, Scotland. 2016. Available from:
http://www.open.edu/openlearncreate/mod/oucontent/view.php?id=53369&section=1.4
Accessed 03/04/17.
61. Global Polio Eradication Initiative. Available from:https://www.polioeradication.org.
Accessed 31/03/17.
20 
62. World Health Organisation. Periodic intensification of routine immunisation: Lessons learned
and implication for action. Immunization, vaccines and biologicals. 2009. Available from:
http://www.immunizationbasics.jsi.com Accessed 18/04/17.
63. Gil Cuesta J, Mukembe N, Valentiner-Branth P, Stefanoff P, Lenglet A. Measles vaccination
coverage survey in moba, katanga, democratic republic of congo, 2013: need to adapt routine
and mass vaccination campaigns to reach the unreached. PLoS Curr. 2015;7.
64. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, et al. First outbreak response
using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of
adverse events, Guinea, 2012. PLoS Negl Trop Dis. 2013;7(10):e2465.
65. Bagonza J, Rutebemberwa E, Mugaga M, Tumuhamye N, Makumbi I. Yellow fever vaccination
coverage following massive emergency immunization campaigns in rural Uganda, May 2011:
a community cluster survey. BMC Pub Health. 2013;13:202.
66. Mounier-Jack S, Burchett HE, Griffiths UK, Konate M, Diarra KS. Meningococcal vaccine
introduction in Mali through mass campaigns and its impact on the health system. Glob Health
Sci Prac. 2014;2(1):117-29.
67. Diallo A, Sow SO, Idoko OT, Hirve S, Findlow H, Preziosi MP, et al. Antibody persistence at
1 and 4 years following a single dose of MenAfriVac or Quadrivalent polysaccharide vaccine
in healthy subjects aged 2-29 years. Clin Infect Dis. 2015; 61:S521-s30
68. Verguet S, Jassat W, Bertram MY, Tollman SM, Murray CJ, Jamison DT, et al. Impact of
supplemental immunisation activity (SIA) campaigns on health systems: findings from South
Africa. Journal Epidemiol Community Health. 2013;67(11):947-52.
69. Hanvoravongchai P, Mounier-Jack S, Cruz VO, Balabanova D, Biellik R, Kitaw Y, et al. Impact
of measles elimination activities on immunization services and health systems: findings from
six countries. J Infect Dis. 2011;204 Suppl 1:S82-S9.
70. Schoub BD, Eggers R, Cameron NA, Coovadia HM. The winter 1996 mass immunisation
campaign--is it the best strategy for South Africa at this time? S Afr Med J. 1996;86(9):1129-
30.
71. Dietz V, Cutts F. The use of mass campaigns in the expanded program on immunization: a
review of reported advantages and disadvantages. Int J Health Serv. 1997;27(4):767-90.
72. Paul P, Fabio A. Literature review of HPV vaccine delivery strategies: considerations for
school- and non-school based immunization program. Vaccine. 2014;32(3):320-6.
73. World Health Organisation. Immunization vaccines and biologicals: School based




74. Moodley I, Tathiah N, Mubaiwa V, Denny L. High uptake of Gardasil vaccine among 9 - 12-
year-old schoolgirls participating in an HPV vaccination demonstration project in KwaZulu-
Natal, South Africa. S Afr Med J. 2013;103(5):318-21.
75. Snyman LC, Dreyer G, Visser C, Botha MH, van der Merwe FH. The Vaccine and Cervical
Cancer Screen project 2 (VACCS 2): Linking cervical cancer screening to a two-dose HPV
vaccination schedule in the South-West District of Tshwane, Gauteng, South Africa. S Afr Med
J. 2015;105(3):191-4.
76. Ogembo JG, Manga S, Nulah K, Foglabenchi LH, Perlman S, Wamai RG, et al. Achieving high
uptake of human papillomavirus vaccine in Cameroon: lessons learned in overcoming
challenges. Vaccine. 2014;32(35):4399-403.
77. Watson-Jones D, Lees S, Mwanga J, Neke N, Changalucha J, Broutet N, et al. Feasibility and
acceptability of delivering adolescent health interventions alongside HPV vaccination in
Tanzania. Health Pol Plan. 2016;31(6):691-9.
78. Raesima MM, Forhan SE, Voetsch AC, Hewitt S, Hariri S, Wang SA, et al. Human
Papillomavirus Vaccination Coverage Among School Girls in a Demonstration Project -
Botswana, 2013. MMWR. 2015;64(40):1147-9.
0 
PART C: MANUSCRIPT 
1 
MANUSCRIPT FORMATTED FOR PLoS MEDICINE 
JOURNAL 
School based versus supplemental vaccination strategies in the 
delivery of vaccines to 5-19 year olds in Africa – a systematic 
review1 
Eposi C. Haddison, MD 
School of Public Health and Family Medicine, University of Cape Town, South Africa 
eposihaddison@yahoo.com 
1 Supervisor: Benjamin Kagina 




Some vaccine preventable diseases still remain a public health burden in many African 
countries. The occurrence of vaccine preventable diseases in all age groups has led to the 
realization of the need to extend routine immunisation services to school age children and 
adolescents. Supplemental immunisation activities (SIAs) and school based vaccination (SBV) 
are two common strategies used to complement the EPI in vaccine delivery. Therefore, this 
review aimed to assess the effectiveness of SIAs compared to SBV in the administration of 
vaccines to 5-19 year olds in Africa.  
Methods and findings 
Systematic review methods (protocol number CRD42017057475) were used to address our 
study aim. Electronic databases were searched up to March 30, 2017 for primary studies 
investigating the delivery of vaccines via SIAs or SBV to 5-19 year olds. To be included in the 
review, studies must have reported any of the following outcomes:  vaccination coverage, cost 
of the vaccination strategy or effect of the strategy on routine immunisation. During the search, 
no restriction was placed on language or the study period. The search was complemented by 
browsing reference lists of potential studies. Out of the 4938 studies identified, 31 studies met 
our inclusion criteria. Both SIAs and SBV showed high vaccination coverage. This result 
should be interpreted with caution due to the high heterogeneity observed across the included 
studies. The SIAs reported a higher coverage of 91% (95% CI: 84%, 98%) than SBV which 
had a coverage of 75% (95% CI: 67%, 83%). In most settings, SBV was reported to be more 
expensive than SIAs.  The SIAs were found to negatively affect routine immunisation services. 
Conclusions 
Both SIAs and SBV are routinely used to complement the EPI in the delivery of vaccines in 
Africa. In settings where school enrolment is suboptimal as is the case in many African 
countries, our results show SIAs may be more effective in reaching school age children and 
adolescents than SBV. The SBV has only been tested in the delivery of two or three dose HPV 
vaccine to adolescent girls, whereas SIAs have been tested in the delivery of different types of 
vaccines. Our results re-iterate the importance of systematic evidence to best inform African 
authorities on the optimal delivery strategies of vaccines targeting school age children and 
adolescents into their immunisation programme. 
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AUTHOR SUMMARY 
Why was this study done? 
 Vaccine preventable diseases (VPDs) are a public health burden in Africa due to low
vaccination coverage.  All age groups are at risk of VPDs in the absence of optimal
vaccination coverage.
 Extension of routine vaccination services to school age children and adolescents has been
recommended by global immunisation organisations in order to fight VPDs. However,
uptake of vaccines in older children and adolescents in Africa is slow, partly due to the
absence of a structured delivery platform.
 To evaluate the use of supplemental immunisation activities (SIAs) and school based
vaccination (SBV) as potential vaccine delivery platforms to school aged children and
adolescents.
What did the researchers do and find? 
 A systematic review was conducted. Several (31) studies were identified that reported any
of the following outcomes: vaccination coverage, cost of vaccine delivery strategy or effect
of either strategy (SIA or SBV) on routine immunisation services.
 The SIAs achieved a higher vaccination coverage than SBV.
 The SBV is a more expensive strategy than SIAs.
 The SIAs negatively affected routine immunisation.
What do these findings mean? 
 In settings where school enrolment is low, SIAs would be a better vaccine delivery option
than SBV.
 Policies on vaccination need to be revised based on the existing local evidence to ensure




The Expanded Programme on Immunisation (EPI) was founded in 1974 to provide 
immunisation services to children both nationally and globally [1]. The EPI has proven to be a 
cost effective public health strategy with reports suggesting that due to the programme, millions 
of infants’ lives have been saved against vaccine preventable diseases (VPDs) [1]. Despite the 
widespread implementation of EPI, some VPDs still remain a public health burden in a majority 
of the African countries[2]. Low vaccination coverage rates in children and the inability to 
reach populations not targeted by the EPI are likely contributors to the high prevalence of VPDs 
in Africa [3, 4].  
Routinely, school aged children and adolescents are not the primary target of EPI and as a 
result, an immunisation gap among this population is observed in many settings  [5]. In this 
light, the WHO recommends several vaccines for school aged children and adolescents to be 
included in national immunisation programmes (NIP). The WHO recommended vaccines to 
older children include HPV, diphtheria, tetanus, pertussis, measles, rubella, hepatitis B and 
meningococcal vaccine [5, 6]. Most High Income Countries (HICs) have implemented these 
WHO recommendations but most Low and Middle Income Countries (LMICs) have not [7-9]. 
Several reasons justify the inclusion of school aged children and adolescents into NIPs. First, 
infants who miss routine vaccinations remain susceptible to VPDs as they grow older [5, 10].  
Second, immunity acquired through infant immunisation for some VPDs like tetanus, 
diphtheria and pertussis wanes over time thus requiring booster doses later in life [11]. Third, 
epidemiological changes have led to a shift in the age group infected by certain VPDs like 
rubella from infancy to adolescence, thus requiring a shift in the age group targeted for 
immunisation [12]. Lastly, new vaccines under development such as against HIV and 
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tuberculosis (TB) are likely to target older children and adolescents. In the absence of 
structured vaccine delivery programs for school age children and adolescents, many settings 
use school based vaccination (SBV) and supplementary immunisation activities (SIAs) to reach 
these groups. 
Supplementary immunisation activities, also known as mass vaccination campaigns refer to an 
immunisation strategy where a large number of people are vaccinated within a defined 
geographical area and period regardless of their previous vaccination status [13]. The success 
of SIAs in outbreak control as well as in the eradication of smallpox is well documented [13-
16]. However, there are reports suggesting negative effects of SIAs on the routine health 
services, including EPI [17, 18]. 
School based vaccination is the vaccination of school children on school premises within 
school hours. This delivery platform is fairly new to the EPI compared to SIAs [19], 
particularly in Africa. Currently in Africa, the main vaccine administered through SBV strategy 
is the HPV vaccine. Among the advantages of SBV are high vaccination coverage and the 
possibility to extend other health services to school age children [20-22]. However, in Africa, 
there are millions of children not attending school [23] and are missed by SBV strategy. 
Therefore our study aimed to compare the effectiveness of using SIA or SBV to deliver 
vaccines to 5-19 year olds in Africa. 
METHODS 
A protocol for this review was developed and adhered to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses Protocol 2015 (PRISMA-P) (S1 Checklist). The 
protocol was registered with PROSPERO (CRD42017057475) [24]. 
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Search strategy 
A search was carried out to identify all relevant studies. Both published and unpublished 
literature was searched up to March 30, 2017. No restriction was placed on the publication 
language or period. The following electronic databases were searched using both medical 
subject headings (MeSH) and free text terms relating to vaccination, children, adolescents and 
Africa (S1 Table); PubMed, Africa Wide, Cochrane Central Register of Controlled trials 
(CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAHL), World 
Health Organization Library Information System (WHOLIS), Web of Science, PDQ (Pretty 
Darn Quick)-Evidence and Scopus. The following grey literature databases were searched for 
reports, non-reviewed and non-published papers; WHO, Gavi, The Vaccine Alliance (GAVI) 
and UNICEF. The reference lists of the included publications were evaluated to identify other 
potential studies. 
Study selection 
The following criteria was used to select primary studies for inclusion: (1) the study was either 
a randomised controlled trial (RCTs), non-RCT, cluster-RCT, interrupted time series, 
controlled before-and-after, cohort, cross-sectional or case-control studies;  (2) participants 
were school aged children to adolescents (5-19 years) living in Africa; (3) supplementary 
immunisation activities (SIAs) or school based vaccination (SBV) were the vaccination 
strategies under  investigation; (4)  vaccination coverage, cost of vaccine delivery or effect of 
either strategy (SIA or SBV) on routine health services including EPI were reported as any of 
the outcomes. Retrieved articles were independently screened by two reviewers (HEC and LA). 
Where eligibility was unclear, a review was carried out by a third independent reviewer (BK). 
The same process was carried out for review of the full text of eligible studies. 
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Data extraction 
HEC and LA independently reviewed each included study and extracted data using a piloted 
data extraction form (S1 Form). Where discrepancies arose HEC, LA and BK reached a 
consensus by discussion.  Corresponding authors were contacted for missing data and some of 
them provided the missing information. 
Quality assessment of included studies 
Experimental studies were assessed using the Cochrane Collaboration’s tool for assessing risk 
of bias [25], while the Hoy et al., modified tool was used for cross-sectional studies [26]. 
Studies using the Cochrane checklist were scored as ‘High risk’ or ‘Low risk’. Those using the 
Hoy et al., checklist were scored as High risk’ or ‘Moderate risk’ or ‘Low risk’ of bias. Studies 
with high risk of bias were rated as poor quality studies while those with moderate and low risk 
of bias were rated as moderate and high quality studies respectively. Where discrepancies 
arose, a consensus was arrived at through discussion by HEC and LA. The nine studies 
reporting data on the costs had variable study designs, some of them with no known tool for 
quality assessments. As our only interest from these studies was the cost of the strategy 
irrespective of the study design, there were no quality assessments done for the nine studies.  
Data synthesis and analysis 
Data was analysed using Stata v. 14.0.  Results from the studies reporting vaccination coverage 
were expressed as percentages. Reported costs of the delivery strategies were standardised to 
United States Dollars (USD) if reported in a different currency. The costs of the strategies (SBV 
or SIA) and their effects on routine vaccination were presented in a narrative form. 
A meta-analysis for vaccination coverage using a random effects model with inverse variance 
proportion was carried out. Pooled statistics for vaccination coverage were expressed as 
proportions with 95% confidence interval (95% CI) as opposed to risk ratios proposed in the 
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protocol because of the study designs of the included studies. Coverage was expressed as a 
prevalence in all studies reporting this outcome and not as a risk hence our decision to report 
proportions. Subgroup analyses were carried to evaluate vaccination coverage per strategy 
stratified by vaccines or study setting. Missing values were imputed in order to enable an 
intention-to-treat analysis. A sensitivity analysis was then carried out where imputations were 
done to see if the result differed from that without imputations. 
Visual inspection of forest plots, the Chi-squared test for homogeneity with a significance level 
set at 10% and the I2 statistic were used to assess and quantify any heterogeneity between study 
results.  Heterogeneity was rated as ‘low’ for ≤ 49% and ‘moderate’ for 50-74% and ‘high’ for 
≥ 75% using the I2 statistic.  
RESULTS 
Literature search 
Three thousand seven hundred and nineteen (3719) studies were identified through searching 
electronic peer reviewed databases. A further 1461 were identified from grey literature. An 
additional five studies were identified from the reference lists of potential articles only. After 
duplicates were removed 4938 studies were left. The titles and abstracts of the 4938 studies 
were screened and 4872 were excluded. The full text of the remaining 65 were retrieved and 
assessed for eligibility. Out of the 65, 31 met our inclusion criteria (Fig 1).  
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Fig. 1. PRISMA flowchart for selection of included studies 
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Characteristics of included studies 
A total of 31 studies were included in our review. There were 20 cross-sectional studies [22, 
27-45], eight economic evaluation studies [46-53], one cluster-randomised trial [54], one
epidemiological report [55] and one interrupted time series [56]. The included studies were 
published between 1993 and 2016 with only three studies published before 2000 [44, 45, 55].  
A total of 17 African countries (Fig.2) and five different vaccines were represented from all 
the included studies are shown. Zanzibar, one of the 17 countries is too small to be shown on 
the map. Except four of the included studies that were written in French [43, 45, 49, 52], the 
rest were in English. One of the study team members (HEC) is French literate and translated 
the four articles. In terms of vaccine delivery strategy, 20 and 11 studies assessed SIAs [28-31, 
33, 35-37, 42-45, 48-53, 55, 56] and SBV [22, 27, 32, 34, 38-41, 46, 47, 54] respectively.  
Fig 2. Countries and vaccine delivery strategies represented by the 31 included studies 
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Risk of bias and quality assessment 
Using the Hoy modified tool, a 10 item scale was used to assess the internal and external 
validity of the 20 cross-sectional studies.  Ninety-five percent (19) of the studies were of high 
quality (low risk of bias) meaning further research is very unlikely to change our confidence in 
the estimate of the study outcomes. Five percent (1) of the studies were of moderate quality 
(moderate risk of bias) meaning further research is likely to have an important impact on our 
confidence in the estimate of the outcomes (Fig 3b). For the internal validity, all the studies 
defined which participants were considered to have been vaccinated (by self-report or 
vaccination card) and used the same data collection tool for all the participants. However, five 
studies did not mention if the tool used was standardised [28, 33, 41, 44, 45]. Ten studies 
collected information from proxies (parents or guardians of vaccinated children) [28-31, 33, 
35, 42-45]. All the studies calculated vaccination coverage as the ‘number vaccinated divided 
by the number of the targeted population’. For the external validity, all the studies had 
representative samples in terms of age and sex. Random sampling was used in all except four 
studies [32, 34, 36, 38].  Similarly, a majority of the studies had a low non-response rate except 
three studies [32, 39, 45]. 
The Cochrane checklist was used to assess the clustered-randomised trial [54] and interrupted 
time series [56] study (Fig 3a).    
12 
Fig 3a. Risk of bias for experimental studies 
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Fig 3b. Risk of bias for cross-sectional studies 
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 Were data collected directly from the participants?
Was an acceptable case definition used in the study?
Was the study instrument valid and reliable?
Was the same mode of data collection used for all participants?
 Was the length of the shortest prevalence period for the parameter of
interest appropriate?
Were the numerator(s) and denominator(s) for the parameter of interest
appropriate?
Was the study's target population a close representation of the national
population in relations to relevant variables
Was the sampling frame a true or close representation of the target
population?
Was some form of random selection used to select the sample?
 Was the likelihood of non-response bias minimal?
Overall risk of bias
Low risk Moderate risk Unclear
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Vaccination coverage 
SIAs: Twelve studies reported vaccination coverage for SIAs. Ten studies were surveys while 
two [55, 56] were census. Three studies reported coverage data on meningitis PsA-TT vaccine 
[28, 29, 43], five on measles vaccine [30, 31, 33, 55, 56], two on yellow fever vaccine [35, 42], 
one on cholera vaccine [37] and one on meningitis A/C vaccine [45]. Vaccination coverage for 
SIAs ranged from 48.5% to 98% (Table 1). 
Table 1. Characteristics of the included studies reporting vaccination coverage for SIAs 
















817 | 782 6-15 95.6% 
Meyer et al., 2015 Urban/rural 
Meningitis 
(PsA-TT) 
10001 | 9741 6-15    97.4% 
Tall et al., 2015 Urban 
Meningitis 
(PsA-TT) 
232 | 210 5-19 90.5% 
Luquero et al., 
2011 
Urban Measles - 5-15 95% 




(bivalent A C) 
850 | 833 5-19 98% 
Gil Cuesta et al., 
2015 
Urban Measles - 5-15 87.4% 
Ohuma et al., 2009 Rural Measles 378 | 334 5-15 88.3% 
Huhn et al., 2005 Displaced 
Yellow Fever 
(17D) 
25230 | 12238 5-14 48.5% 





- 5-14 62.1% 
Bagonza et al., 
2013 
Rural Yellow Fever 201 | 197 5-15 98% 
CDC, 1999 Urban/rural Measles 4045498 | 3495415 5 -14 86% 
Verguet et al., 
2013 
Urban/rural Measles 10383500 | 7579955 5-14 73% 
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 A meta-analysis of a pooled estimate of coverage was conducted (Fig 4). A pooled estimate 
of 86% (95% CI: 80%, 93%) was observed.  Three studies were excluded from the pooled 
meta-analysis due to missing sample sizes [30, 31, 37]. However, after imputation of the 
sample sizes no major difference was seen in the pooled coverage (Fig 5). 
Fig. 4. Forest plot showing vaccination coverage for SIAs 
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Fig 5. Forest plot showing vaccination coverage for SIAs with imputed data 
SBV: Eight studies reported vaccination coverage for school based vaccination (Table 2). All 
the studies reported coverage of the HPV vaccine among girls aged 9-19 years. Four studies 
reported a combination of a grade and age based approach for identifying the target girls for 
the vaccination [27, 32, 34, 54] while three reported a grade based only approach [22, 39, 40]. 
Vaccination coverage of completed doses among the targeted population ranged from 42.4 – 
97.4%.  A meta-analysis of the studies gave a pooled coverage of 75% (95% CI: 67, 83) (Fig 
6). 
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Table 2. Characteristics of included studies reporting vaccination coverage for SBV 
First author 












Raesima et al., 
2015 
Urban HPV Grade/Age 2488 | 1967 9-14+ 79% 
Binagwaho et 
al., 2012 
Urban/rural HPV Grade 94141 | 88927 12 94.4% 
Moodley et al., 
2013 
Rural HPV Grade/Age 963 | 938 9-14 97.4% 
Snyman et al., 
2015 
Rural HPV Grade/Age 965 | 495 9-14 51.2% 
Botha et al., 
 2015 
Urban/rural HPV Grade 3465 | 1859 9-12 53.7% 
Watson-Jones et 
al., 2012 
Urban/rural HPV Grade/Age 5532 | 4211 12-13 76.1% 
La Montagne et 
al., 2011 
Rural HPV Grade 
2008: 
3459 | 3131 
2009: 




Katagwa et al., 
2014 
Rural HPV Age 415 | 176 9-19 42.4% 
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Fig. 6. Forest plot showing vaccination coverage for SBV 
Comparison of vaccination coverage: To compare the two vaccine delivery strategies, pooled 
estimates for SIAs (mass campaigns) and SBV were evaluated. The SIAs and SBV had a 
pooled coverage of 91% and 75%; respectively. (Fig 7). For this comparison and subsequent 
analyses, Huhn et al.’s, study [35] was not included in the meta-analysis as the targeted 
population (displaced) in the study is not the routine group for SIAs.         
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Fig. 7. Comparison of vaccination coverage per strategy 
Subgroup analyses for vaccination coverage 
Subgroup analyses were carried out to evaluate if vaccination coverage varied by setting in the 
case of both strategies or by vaccine for SIAs. 
Setting: For SIAs, vaccination coverage did not vary much per setting (Fig 8). Coverage was 
highest in urban areas (97%, 95% CI: 96, 98) and lowest in a mixed setting (88%, 95% CI: 79, 
98). 
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Similarly for SBV, there was little variation of coverage across setting. Coverage in urban areas 
represented by one study was 79% (95% CI: 77, 81), rural areas 74% (95% CI: 63, 85) and 
mixed settings 75% (53, 97). 
Fig 8. Subgroup analysis of SIA coverage per setting 
Vaccine: There was some variation in coverage with regards to the vaccine (Fig 9). Measles 
campaigns reported the lowest coverage 83% (95% CI: 72, 93). Meningitis campaigns had a 
coverage of 96%, (95% CI: 94, 98) while the only study on yellow fever reported a coverage 
of 98% (95% CI: 95, 99).  
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Fig 9. Subgroup analysis of SIA coverage per vaccine 
Cost of vaccine delivery strategy 
SIAs: Seven studies reported the cost of organising SIAs (Table 3). These results represent the 
costs spent on the total target population for the campaign. It was not feasible to separate the 
amount spent for 5-19 year olds only. The campaigns targeted people aged 6 months and older 
with the number of vaccinated people across all studies ranging from 23921 to 12,649,448. The 
vaccines administered were against measles, cholera, meningitis A/C and yellow fever and all 
were administered as a single dose. Two studies reported on campaigns where two vaccines 
were administered simultaneously [48, 52].  
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A majority of the total cost across the studies was used to procure vaccines and consumables. 
The highest proportion (86%) was reported by da Silva et al., for the combined yellow fever 
and meningitis A/C campaign in Senegal [52].  Salaries of health staff and international 
supervisors were another source of high expenditure. Other reported minor expenses included 
training of personnel, social mobilisation, transport, maintenance of equipment, cold chain and 
management of AEFI. 
SBV: Two studies reported the cost of HPV vaccination in Tanzania and Uganda [46, 47] 
(Table 3). In Tanzania, 4211 girls were vaccinated with three doses of HPV vaccine either 
based on age or class. Schools were chosen from both urban and rural settings. The total 
economic cost for the project was 349,400 USD. The vaccine cost 5 USD/dose. The total cost 
per fully immunised girl in urban areas were 66 USD and 100 USD for class-based and age-
based approach respectively; and in rural areas, 78 USD and 107 USD for class-based and age-
based approach respectively. Administration and supervision (salaries) of the project and 
procurement of vaccines accounted for the major expenses. The reported minor expenses in the 
study included training, cold chain, waste management and social mobilisation. In Uganda, 
3038 girls in a rural setting were vaccinated with three doses of HPV vaccine using a class 
based approach. The total economic cost (cost of all resources used regardless of who paid) 
was 30,646 USD. The vaccine cost 0.2 USD/dose. The total economic cost per fully immunised 
girl was 9.5 USD. Salaries of staff accounted for the greatest part of the cost followed by micro-
planning, staff training, community mobilisation (start-up costs). Other expenses included 
supplies, cold chain, vehicles and transportation. 
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Table 3. Characteristics of included studies reporting the cost of the vaccination strategy 
First author 















Major sources of 
expenditure (%) 
School based vaccination 
Quentin et al., 
2012 
Urban/Rural 12-13 HPV 4,211 349,367 66-107 
Salaries (42) 
Procurement (34) 
Levin et al., 
2013 
Rural Grade 5 HPV 3,038 306,463 9.5 
Salaries (40) 
Start-up costs (27) 
Supplemental immunisation activities 
Verguet et al., 
2013 
Urban/Rural 5 - 14 
Measles/ 
Polio 




et al., 2009 
Urban > 6 months Yellow fever 2,610,994 2,382,582 0.9 
Vaccines and 
consumables (80.6) 
Legros et al., 
1999 




















85,925 62,055.44 72.2 
Vaccines and 
consumables (86) 
Uzicanin et al., 
2004 
Urban/rural 














Schaetti et al., 
2012 






Effect on routine immunisation 
SIA: Two studies reported the effect of SIAs on routine immunisation and health services. 
Mounier-Jack et al., reported on a 10 day meningitis A campaign in Mali, in 2010 [36] while 
Verguet et al., reported on a 3 weeks measles campaign in South Africa in the same year [56]. 
Both SIAs reported a negative effect on routine immunisation (Table 4).  
Low attendance: Both studies reported a decrease in the number of children attending the child 
clinics during the vaccination period. Mounier-Jack et al., reported a 71-74% decrease in the 
number of children vaccinated during the campaign [36] while Verguet et al.. reported an 8% 
decrease in the number of children who were weighed [56].  
Redeployment of health staff: During the SIAs, staff in charge of routine immunisations were 
either deployed as supervisors for the campaign. This led to the closure of routine immunisation 
services in some districts during the campaign period. 
 Cold chain management: In Mali, routine vaccines were relocated and stored at the regional 
and district level so fridges could be made available to store the campaign vaccine [36]. 
SBV: One study in Rwanda reported on the effect of  HPV vaccination on routine immunisation 
[38] (Table 4). According to Torres-Rueda et al., the vaccination activity which lasted 2 days
had no effect on routine immunisation services [38]. There was no change in the demand for 
routine immunisation and health services.  
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Table 4. Characteristics of included studies reporting effect on routine immunisation 
DISCUSSION 
Both SIAs and SBVs are supplementary EPI programs in many settings, including Africa. Our 
results show both strategies attain high coverage with SIAs showing greater coverage than 
SBVs. However, we showed SIAs negatively affect the provision of routine health services, 
particularly the EPI. In settings like Africa where many resource challenges prevail, the use of 
both SIAs and SBVs to reach school age and adolescents is questionable. 
The high coverage achieved by SIAs reported in this review corroborates with the past 
successes of smallpox eradication, achieved by complementing EPI with SIAs [57]. 
Interestingly, coverage of the SIAs was high irrespective of the vaccine and setting, and this 
attests to the robustness of the strategy. Despite being a new strategy in Africa and being used 
First author 
and year of 
publication 




Supplemental immunisation activities 
Mounier-Jack 





Negative effect. Fewer 
children vaccinated through 
routine immunisation during 
vaccination campaign than 
expected. 




Urban/rural Measles 3 weeks 
Negative effect. 
The use of child health 
services decreased during 
the vaccination campaign 
School based vaccination 
Torres-Rueda 
et al., 2016 
Rwanda Urban/rural HPV 2 days 
No or minimal effect. 
Routine immunisation 
continued during the 
vaccination campaign with 
the same demand for 
services. 
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for the introduction of HPV vaccines, SBV was able to achieve a high coverage. Our findings 
are similar to those obtained in HICs where the SBV strategy is more established and used for 
routine immunisation to this age group [58].  
In terms of vaccine coverage, our review supports what is already known: both SIAs and SBV 
are good options to complement the EPI. However, other factors such as the costs of the 
strategy, school attendance and existing immunisation policies have to be taken into 
consideration when deciding which of the two strategies to use in any given setting. Local 
evidence should be used to evaluate which vaccine delivery strategy is more optimal to reach 
school age children and adolescents in Africa.  
SBV is likely to be more cost-effective than SIAs in countries with high school enrolment. In 
this review, countries reporting SBV coverage had national primary school attendance rates 
ranging from 84.2-98.5% during the period the SBV projects were carried out [59]. Similarly, 
SBV is likely to be optimal in countries with strong inter-ministerial collaboration. 
Collaboration between health and education sectors is crucial to ensure smooth implementation 
of SBV strategies [60].  Conversely, SBV strategy is unlikely to be optimal in countries without 
sufficient financial commitment. School based vaccination has been reported to be an 
expensive strategy which may be feasible on a small scale but not sustainable at a national level 
[61]. Our findings support reports that SBV is an expensive strategy.  
Supplemental immunisation activities, could be the preferred strategy in countries where 
campaigns are regularly used to complement infant immunisation. The experience in 
organising SIAs and community awareness of this strategy can be used to extend the 
vaccination services to school age children and adolescents. Additionally, the SIAs are able to 
reach non-school going children.  Majority of African countries have millions of non-school 
going children who will miss vaccines delivered by SBV programs. The negative impact of 
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SIAs on routine immunisation and health services due to the overlapping of resources (financial 
and human) and duration of the campaigns is a key concern that should be minimized wherever 
SIAs are used. 
Strengths and limitations 
We comprehensively and systematically searched as well as used data from peer-reviewed and 
non-reviewed sources. This study adhered to the PRISMA guidelines of conducting systematic 
reviews. Nonetheless, our review had several limitations. Firstly, we missed a lot of 
information on vaccination coverage because age specific coverage was not reported in some 
of the retrieved studies. Secondly, we observed a high heterogeneity during the meta-analysis. 
The heterogeneity was likely due to differences across studies of factors such as the age groups 
included, study designs, settings and period. This high heterogeneity calls for caution when 
interpreting the coverage achieved by both strategies. Thirdly, the only vaccine administered 
via SBV was the HPV vaccine which is a new and more expensive vaccine administered in 
several doses. These characteristics probably render HPV less acceptable than older vaccines 
used during SIAs thus accounting for some of the differences observed in terms of SBV 
coverage. Fourthly, the absence of a harmonised method of analysing the costs of SIAs and 
SBVs may have accounted for some of the differences in cost observed across countries. Lastly, 
few studies were found reporting the effect of SIAs or SBV on routine immunisation and health 
services so our findings may not reflect the true effect.  
Implication for policy and research 
Local evidence is crucial in the review and development of immunisation policies. Both SIAs 
and SBVs are routinely used in Africa to vaccinate older children. In settings where school 
enrolment is low as is the case in many African countries, our results show SIAs may be more 
effective in reaching school age children and adolescents than SBV. In Africa, the SBV has 
mainly been tested in the delivery of two or three dose HPV vaccine to adolescent girls while 
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SIAs have been used for diverse vaccines and on a larger scale. Further research is therefore 
needed to assess the sustainability of SBV for nationwide delivery of vaccines to school age 
children and adolescent in resource constraint settings that are prevalent in Africa. As 
discussed, one vaccine delivery strategy will not be optimal in all African countries. Our results 
re-iterate the importance of systematic evidence to best inform African authorities on the 
optimal delivery strategies of vaccines targeting school age children and adolescents into the 
immunisation programme. 
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group (b) effect estimates and confidence intervals, ideally with 




21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
14-21
Risk of bias 
across studies 
22 Present results of any assessment of risk of bias across 




23 Give results of additional analyses, if done (e.g., sensitivity or 





24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy 
makers).  
26 
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
28 
Conclusions 26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research.  
28 
FUNDING 
Funding 27 Describe sources of funding for the systematic review and 
other support (e.g., supply of data); role of funders for the 
systematic review.  
na 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.
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S1 Table. SEARCH STRATEGY 
Search terms 
#4 #1 AND #2 AND #3 
#3 Angola OR Republic of Angola OR Algeria OR The People's Democratic 
Republic of Algeria OR Botswana OR Benin OR Dahomey OR Republic of 
Benin OR Burkina Faso OR Burkina OR Republic of Upper Volta OR Burundi 
OR Republic of Burundi OR Central African Republic OR Chad OR Republic 
of Chad OR Cameroon OR Republic of Cameroon OR Republic of Cameroun 
OR Cote D'ivoire OR Ivory Coast OR Republic of Cote D'ivoire OR 
Jamahiriya OR Djibouti OR Republic of Djibouti OR Arab Republic of Egypt 
OR Egypt OR Democratic Republic of the Congo OR DR Congo OR Congo-
Kinshasa OR DRC OR Zaire OR Eritrea OR State of Eritrea OR Ethiopia OR 
Federal Democratic Republic of Ethiopia OR The Gambia OR Republic of the 
Gambia OR Ghana OR Republic of Ghana OR Gabon OR Gabonese Republic 
OR Guinea OR Republic of Guinea OR Guinea-Conakry OR Guinea-Bissau 
OR Republic of Guinea-Bissau OR Kenya OR Republic of Kenya OR Liberia 
OR Republic of Liberia OR Madagascar OR Republic of Madagascar OR 
Malawi OR Republic of Malawi OR The Warm Heart of Africa OR Mali OR 
Republic of Mali OR Mozambique OR Republic of Mozambique OR Libya 
OR State of Libya OR South Africa OR Tunisia OR Namibia OR Lesotho OR 
Kingdom of Lesotho OR Mauritania OR Mauritius OR Mayotte OR Morocco 
OR Kingdom of Morocco OR Nigeria OR Federal Republic of Nigeria OR Sao 
Tome and Principe OR Democratic Republic of Sao Tome and Principe OR 
Senegal OR Republic of Senegal OR Seychelles OR Sudan OR Republic of the 
Sudan OR North Sudan OR Swaziland OR Kingdom of Swaziland OR 
Ngwane OR Niger OR Republic of Niger OR Rwanda OR Republic of 
Rwanda OR Sierra Leone OR Republic of Sierra Leone OR Somalia OR 
Federal Republic of Somalia OR South Sudan OR Republic of South Sudan 
OR  St Helena OR Tanzania OR United Republic of Tanzania OR Republic of 
Tanganyika and Zanzibar OR Togo OR Togolese Republic OR Uganda OR 
Republic of Uganda OR Western Sahara OR Zambia OR Republic of Zambia 
OR Zimbabwe OR Republic of Zimbabwe OR Rhodesia 
# 2 Child [MeSH] OR Adolescent [MeSH] OR children OR teenagers 
#1 Mass vaccination [MeSH] OR Mass immunization OR Mass vaccination OR 
vaccination campaigns OR immunization campaigns OR Supplemental 
immunisation activities OR school immunisation programs OR school 
vaccination strategies 
4 
S1 Form: DATA EXTRACTION FORM 
 Please fill in the relevant spaces and tick the right box. Indicate the page reference for each 
data collected in the provided space. 
Section A: Details of data extractor 
1. Name:_______________________________________________________
2. Extraction date:…… ……………………………
Section B: Study eligibility 
1. Study ID (First author and year):_____________________________________________
2. Title of study and publication reference:_______________________________________
__________________________________________________________________________
__________________________________________________________________________ 
3. Corresponding author’s name and contact details:_______________________________
__________________________________________________________________________
4. Type of study design (eg. RCT):_____________________________________________
5. Is the study carried out in Africa?..............................Yes       No  
6. Does the study focus on supplemental immunisation activities or school based
vaccination programmes?..........................................Yes     No  
7. Does the study target children aged 5 – 19 years?.....Yes       No  
8. Does the study report the following outcomes:
 Vaccination coverage of the strategy used…….........Yes      No  
 Cost of vaccines used……………………………......Yes     No  
 Use of routine immunisation and health services before the vaccination activity……… 
………………………………………………………..Yes      No 
 Use of routine immunisation and health services after the vaccination activity………... 
………………………………………………………..Yes     No  
Decision:………………………………….Accepted               Rejected 
Reason for rejection (if applicable):_____________________________________________ 
D   D    M   M   Y     Y    Y     Y 
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Section C: Participants 
1. Targeted age group:___________________________________
Gender:………………Male  Female    Both  
Setting:…….Rural         Urban           Displaced       Other  
Notes:_____________________________________________________________________
__________________________________________________________________________ 
Section D: Intervention/Comparator 
1. Type of strategy:………………………SIA           School based 
2. Objective of the strategy:___________________________________________________
__________________________________________________________________________
3. Name of vaccine used:___________________________________________
4. Duration of the strategy: Start date _____________________(dd/mm/yyyy)
   End date _____________________ (dd/mm/yyyy)     
5. Number of vaccinators used: __________________
6. Profession of vaccinators:………………Doctors   Nurses  
Community health workers       Others (specify)___________________       
7. Method of sensitisation for the vaccination activity:        Media          Letters to 




Section E: Outcomes 
1. Number of children/adolescents:  Male         Female          Total 
targeted: _______       _______        _______
vaccinated: _______       _______        _______
2. Reported vaccination coverage: _________________
3. Number of reported adverse events following immunisation: ___________
4. Cost of the vaccine used (in reported currency): ______________________
5. Cost of the vaccination strategy (if reported): ________________________
(NB. Duplicate 1-5 if vaccination activity carried out in several sessions)
6. Number of children/adolescents targeted for routine immunisation and health services in
the catchment area: _______________________
7. Number of children/adolescents using routine immunisation and health services before
the campaign: ___________________________
6 
8. Number of children/adolescents using routine immunisation and health services after the
campaign: _______________________________
Conclusion from authors: ______________________________________________________ 
___________________________________________________________________________




S1 Text. PLOS MEDICINE SUBMISSION GUIDELINES 
Style and format 
Length Manuscripts can be any length. There are no restrictions on word count, 
number of figures, or amount of supporting information.  
We encourage you to present and discuss your findings concisely. 
Font Use a standard font size and any standard font, except for Symbol font. 
Headings Limit manuscript sections and sub-sections to 3 heading levels. Make sure 
heading levels are clearly indicated in the manuscript text. 
Layout and 
spacing 
Manuscript text should be double-spaced. 
Do not format text in multiple columns. 
Page and line 
numbers 
Include page numbers and line numbers in the manuscript file. Use 
continuous line numbers (do not restart the numbering on each page). 
Footnotes Footnotes are not permitted. If your manuscript contains footnotes, move 
the information into the main text or the reference list, depending on the 
content. 
Language Manuscripts must be submitted in English. 
You may submit translations of the manuscript or abstract as supporting 
information. Read the supporting information guidelines. 
Abbreviations Define abbreviations upon first appearance in the text. 
Do not use non-standard abbreviations unless they appear at least three 
times in the text. List all non-standard abbreviations (with definitions) in 
alphabetical order in a separate section at the beginning of the manuscript. 
Keep abbreviations to a minimum. 
Reference style PLOS uses “Vancouver” style, as outlined in the ICMJE sample 
references. 
See reference formatting examples and additional instructions below. 
Manuscript organisation 
Abstract 
The Abstract comes after the title page in the manuscript file. The abstract text is also entered 
in a separate field in the submission system.   
The research article Abstract is divided into the following three sections: Background, 
Methods and Findings, and Conclusions. It should contain all the following elements (items 
in square brackets are needed only for some study types). 
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Please use the same format for abstracts submitted as presubmission inquiries. PLOS 
Medicine does not have a specific length requirement for abstracts submitted as part of the 
manuscript, but no more than 300 words can be submitted in the online interface of the 
manuscript submission system. If abstracts are longer than 300 words, please submit the first 
300 words to the system. 
Background 
This section should clearly describe the rationale for the study. It should end with a statement 
of the specific study hypothesis and/or study objectives. 
Methods and Findings 
 Describe the study participants or what was studied (e.g., patient population, cell
lines; be as specific as possible, including numbers of individuals studied). Describe
the study design, intervention if applicable, main methods used, primary outcome
measure(s), and length of follow up if applicable.
 [If appropriate, include how many participants were assessed out of those enrolled.
For survey research, include the response rate.]
 [If critical to the understanding of the paper, describe how results were analyzed, i.e.,
which specific statistical tests were used.]
 Describe the main outcomes and quantify the results using a measure of precision
(e.g., 95% confidence interval). Describe any adverse events.
 Describe the main limitations of the study.
Conclusions 
 Provide a general interpretation of the results with any important recommendations
for future research.
 [For a clinical trial, provide any trial identification number(s) and name(s) (e.g., trial
registration number, protocol number or acronym).]
Introduction 
The Introduction should put the focus of the manuscript into a broader context. As you 
compose the Introduction, think of readers who are not experts in this field. Include a brief 
review of the key literature. If there are relevant controversies or disagreements in the field, 
they should be mentioned so that a non-expert reader can delve into these issues further. The 
Introduction should conclude with a brief statement of the overall aim of the experiments and 
a comment about whether that aim was achieved. 
Methods 
The Methods should provide enough detail for reproduction of the findings. Protocols for 
new methods should be included, but well-established methodological procedures may 
simply be referenced. A full description of the methods should be included in the manuscript 
itself rather than in a supplemental file. 
Methods should also include a section with descriptions of any statistical methods used. The 
description should conform to the criteria outlined by the Uniform Requirements, as follows: 
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Describe statistical methods with enough detail to enable a knowledgeable reader with 
access to the original data to judge its appropriateness for the study and to verify the 
reported results. When possible, quantify findings and present them with appropriate 
indicators of measurement error or uncertainty (such as confidence intervals). Avoid relying 
solely on statistical hypothesis testing, such as P values, which fail to convey important 
information about effect size and precision of estimates. References for the design of the 
study and statistical methods should be to standard works when possible (with pages stated). 
Define statistical terms, abbreviations, and most symbols. Specify the statistical software 
package(s) and versions used. Distinguish prespecified from exploratory analyses, including 
subgroup analyses.  
Submit detailed protocols for newer or less established methods. Well-established protocols 
may simply be referenced. Protocol documents for clinical trials, observational studies, and 
other non-laboratory investigations may be uploaded as supporting information. 
We recommend and encourage you to deposit laboratory protocols in protocols.io, where 
protocols can be assigned their own persistent digital object identifiers (DOIs). 
To include a link to a protocol in your article: 
1. Describe your step-by-step protocol on protocols.io
2. Select Get DOI to issue your protocol a persistent digital object identifier (DOI)
3. Include the DOI link in the Methods section of your manuscript using the following
format provided by protocols.io:
http://dx.doi.org/10.17504/protocols.io.[PROTOCOL DOI]
At this stage, your protocol is only visible to those with the link. This allows editors and 
reviewers to consult your protocol when evaluating the manuscript. You can make your 
protocols public at any time by selecting Publish on the protocols.io site. Any referenced 
protocol(s) will automatically be made public when your article is published. 
Results 
The Results section should include all primary and secondary outcome measures analyzed. 
The section may be divided into subsections, each with a concise subheading. Tables and 
figures central to the study should be included in the main paper. The Results section should 
be written in past tense. 
PLOS journals require authors to make all data underlying the findings described in their 
manuscript fully available without restriction, with rare exception. 
Large data sets, including raw data, may be deposited in an appropriate public repository. See 
our list of recommended repositories. 
For smaller data sets and certain data types, authors may provide their data within Supporting 
Information files accompanying the manuscript. Authors should take care to maximize the 
accessibility and reusability of the data by selecting a file format from which data can be 
efficiently extracted (for example, spreadsheets or flat files should be provided rather than 
PDFs when providing tabulated data). 
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For more information on how best to provide data, read our policy on data availability. PLOS 
does not accept references to “data not shown.” 
As outlined in the Uniform Requirements: 
Give numeric results not only as derivatives (for example, percentages) but also as the 
absolute numbers from which the derivatives were calculated, and specify the statistical 
significance attached to them, if any. Restrict tables and figures to those needed to explain 
the argument of the paper and to assess supporting data. Use graphs as an alternative to 
tables with many entries; do not duplicate data in graphs and tables. Avoid nontechnical uses 
of technical terms in statistics, such as “random” (which implies a randomizing device), 
“normal,” “significant,” “correlations,” and “sample.”  
Discussion 
The Discussion should be concise and tightly argued. It should start with a brief summary of 
the main findings. It should include paragraphs on the generalizability, clinical relevance, 
strengths, and limitations of your study. 
You may wish to discuss the following points also: 
 How do the conclusions affect the existing knowledge in the field?
 How can future research build on these observations and what are the key
experiments that must be done?
Acknowledgments 
Those who contributed to the work but do not meet our authorship criteria should be listed in 
the Acknowledgments with a description of the contribution. 
Authors are responsible for ensuring that anyone named in the Acknowledgments agrees to 
be named. 
Do not include funding sources in the Acknowledgments or anywhere else in the manuscript 
file. Funding information should only be entered in the financial disclosure section of the 
submission system.  
References 
Any and all available works can be cited in the reference list. Acceptable sources include: 
 Published or accepted manuscripts
 Manuscripts on preprint servers, if the manuscript is submitted to a journal and also
publicly available as a preprint
Do not cite the following sources in the reference list: 
 Unavailable and unpublished work, including manuscripts that have been submitted
but not yet accepted (e.g., “unpublished work,” “data not shown”). Instead, include
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those data as supplementary material or deposit the data in a publicly available 
database. 
 Personal communications (these should be supported by a letter from the relevant
authors but not included in the reference list)
References are listed at the end of the manuscript and numbered in the order that they appear 
in the text. In the text, cite the reference number in square brackets (e.g., “We used the 
techniques developed by our colleagues [19] to analyze the data”). PLOS uses the numbered 
citation (citation-sequence) method and first six authors, et al. 
Do not include citations in abstracts or author summaries. 
Make sure the parts of the manuscript are in the correct order before ordering the citations. 
Formatting references 
Because all references will be linked electronically as much as possible to the papers they 
cite, proper formatting of the references is crucial.   
PLOS uses the reference style outlined by the International Committee of Medical Journal 
Editors (ICMJE), also referred to as the “Vancouver” style. Example formats are listed 
below. Additional examples are in the ICMJE sample references. 
A reference management tool, EndNote, offers a current style file that can assist you with the 
formatting of your references. If you have problems with any reference management 
program, please contact the source company's technical support.  
Journal name abbreviations should be those found in the National Center for Biotechnology 




Hou WR, Hou YL, Wu GF, Song Y, Su XL, Sun B, et al. cDNA, 
genomic sequence cloning and overexpression of ribosomal protein gene 
L9 (rpL9) of the giant panda (Ailuropoda melanoleuca). Genet Mol Res. 
2011;10: 1576-1588. 
Devaraju P, Gulati R, Antony PT, Mithun CB, Negi VS. Susceptibility to 
SLE in South Indian Tamils may be influenced by genetic selection 
pressure on TLR2 and TLR9 genes. Mol Immunol. 2014 Nov 22. pii: 
S0161-5890(14)00313-7. doi: 10.1016/j.molimm.2014.11.005 
Note: A DOI number for the full-text article is acceptable as an 




Same as published articles, but substitute “Forthcoming” for page 
numbers or DOI. 
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Source Format 
Web sites or 
online articles 
Huynen MMTE, Martens P, Hilderlink HBM. The health impacts of 
globalisation: a conceptual framework. Global Health. 2005;1: 14. 
Available from: http://www.globalizationandhealth.com/content/1/1/14. 
Books Bates B. Bargaining for life: A social history of tuberculosis. 1st ed. 
Philadelphia: University of Pennsylvania Press; 1992. 
Book chapters Hansen B. New York City epidemics and history for the public. In: 
Harden VA, Risse GB, editors. AIDS and the historian. Bethesda: 
National Institutes of Health; 1991. pp. 21-28. 
Deposited 
articles (preprint
s, e-prints, or 
arXiv)  
Krick T, Shub DA, Verstraete N, Ferreiro DU, Alonso LG, Shub M, et 
al. Amino acid metabolism conflicts with protein diversity; 1991. 
Preprint. Available from: arXiv:1403.3301v1. Cited 17 March 2014. 
Published media 




Fountain H. For Already Vulnerable Penguins, Study Finds Climate 
Change Is Another Danger. The New York Times. 29 Jan 2014. 
Available from: 
http://www.nytimes.com/2014/01/30/science/earth/climate-change-
taking-toll-on-penguins-study-finds.html. Cited 17 March 2014. 
New media 
(blogs, web sites, 
or other written 
works) 
Allen L. Announcing PLOS Blogs. 2010 Sep 1 [cited 17 March 2014]. 
In: PLOS Blogs [Internet]. San Francisco: PLOS 2006 - . [about 2 





Wells A. Exploring the development of the independent, electronic, 
scholarly journal. M.Sc. Thesis, The University of Sheffield. 1999. 




Roberts SB. QPX Genome Browser Feature Tracks; 2013 [cited 2013 





or TV shows) 
Hitchcock A, producer and director. Rear Window [Film]; 1954. Los 
Angeles: MGM. 
Supporting Information 
Authors can submit essential supporting files and multimedia files along with their 
manuscripts. All supporting information will be subject to peer review. All file types can be 
submitted, but files must be smaller than 10 MB in size. 
Authors may use almost any description as the item name for a supporting information file as 
long as it contains an “S” and number. For example, “S1 Appendix” and “S2 Appendix,” “S1 
Table” and “S2 Table,” and so forth.   
Supporting information files are published exactly as provided, and are not copyedited. 
Supporting information captions 
13 
List supporting information captions at the end of the manuscript file. Do not submit captions 
in a separate file. 
The file number and name are required in a caption, and we highly recommend including a 
one-line title as well. You may also include a legend in your caption, but it is not required. 
Example caption 
S1 Text. Title is strongly recommended. Legend is optional. 
In-text citations 
We recommend that you cite supporting information in the manuscript text, but this is not a 
requirement. If you cite supporting information in the text, citations do not need to be in 
numerical order. 
Read the supporting information guidelines for more details about submitting supporting 
information and multimedia files.  
Figures and Tables 
Figure files 
If you are submitting a new manuscript, embed each figure in the manuscript in read 
order, immediately following the paragraph where the figure is first mentioned and above the 
related figure caption. 
Upon revision, each figure must be prepared and submitted to the submission system as an 
individual file. Additionally, embed the same figures in the manuscript in read order, and 
ensure that they match the figure files that you uploaded. 
Upon acceptance, figure files should be uploaded to the submission system, with no 
embedded figures in the manuscript. 
Figure citations 
Cite figures in ascending numeric order upon first appearance in the manuscript file. 
Systematic reviews and meta-analyses 
Reports of systematic reviews and meta-analyses must adhere to the PRISMA Statement or 
alternative guidelines appropriate to the study design, and include the completed checklist 
and flow diagram to accompany the main text. Authors must complete the appropriate 
reporting checklist not only with page references, but also with sufficient text excerpted from 
the manuscript to explain how they accomplished all applicable items. 
Abstracts should follow PRISMA for Abstracts, using the PLOS abstract format. Authors 
must also state within the Methods section of their paper whether a protocol exists for their 
systematic review, and if so, provide a copy of the protocol as supporting information. 
14 
The journal supports the prospective registration of systematic reviews. Authors whose 
systematic review was prospectively registered (e.g., in a registry such as PROSPERO) 
should provide the registry number in their abstract. Registry details and protocols will be 
made available to editors and reviewers, and included with the paper if the report is 
ultimately published. 
